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Abstract 
Influenza A virus (IAV) is a negative sense, single-stranded, segmented RNA virus with 
eight gene segments. It is an important respiratory pathogen which causes annual epidemics and 
occasional pandemics worldwide in humans and leads to considerable economic problems for the 
livestock industry. To control and prevent this significant disease, understanding the 
pathogenesis of IAVs is critical. Although some molecular mechanisms regarding virulence have 
been determined, IAV pathogenesis is not completely understood and is difficult to predict.  
The eight viral gene segments of IAV were thought to encode for 10 viral proteins.  Since 
2001, eight additional viral proteins have been identified, including PB1-F2, PB1-N40, PA-X, 
NS3, PA-N155, PA-N182, M42, and PB2-S1. However, the functions of these novel proteins in 
influenza virus replication as well as pathogenesis have not been fully elucidated.  
Although PB1-F2 protein is an important virulence factor of IAV, the effects of this 
protein on viral pathogenicity of swine influenza virus (SIV) remain unclear. In Chapter 2, we 
investigated the contribution of the PB1-F2 protein to viral pathogenicity of a virulent triple-
reassortant (TR) H1N1 SIV in different hosts, pigs and mice. Our data indicate that PB1-F2 
expression in virulent TR H1N1 SIV modulates virus replication and pathogenicity in the natural 
host, pigs, but not in mice. In addition, single amino acid (aa) substitution at position 66 (N/S) in 
the PB1-F2 has a critical role in virulence in mice but no effect was found in pigs.  
A novel IAV protein, PA-X consists of the N-terminal 191aa of PA protein and a unique 
C-terminal 41 (truncated form) or 61 (full-length form) aa residues encoded by +1 ribosomal 
frameshifting. Although several studies have demonstrated the PA-X protein as an important 
immune modulator and virulence factor, the impact of different expressions of PA-X protein 
including full-length, truncated or PA-X deficient forms on viral pathogenicity and host response 
  
remains unclear. In Chapter 3, we showed that expression of either truncated or full-length PA-X 
protein in 2009 human pandemic H1N1 (pH1N1) viruses suppresses host antiviral response by 
host shutoff activity which promotes viral growth and virulence in mice when compared to loss 
of PA-X expression. Furthermore, full-length PA-X expression displayed stronger impact on 
viral pathogenicity and host immune response compared to truncated PA-X expression.   
Taken together, our results provide new insights into the impact of PB1-F2 and PA-X 
proteins on virus replication, pathogenicity and modulation of host immune responses. This 
knowledge is important for better understanding of IAV pathogenesis.   
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Chapter 1 - General Introduction 
 1.1 Influenza  
Influenza is an important acute respiratory disease caused by influenza viruses in humans 
and animals. Although the disease outcome is usually mild in humans with common symptoms, 
including fever, cough and runny nose, influenza virus infection can also cause severe symptoms 
such as pneumonia and death. In animals, the severity of disease varies from asymptomatic 
infection to severe clinical signs and high mortality, depending on the species, virus strains and 
host immune condition.      
 1.2 Influenza virus classification 
Influenza viruses are single-stranded, negative-sense RNA viruses which belong to the 
Orthomyxoviridae family. There are three genera of influenza viruses, including influenza A, B 
and C viruses. Influenza A and B viruses have similar spherical or filamentous shapes in contrast 
to influenza C viruses which have distinct cordlike long structures. Influenza A and B have eight 
RNA segments, while influenza C contains only seven genome segments. In addition, influenza 
A and B have two major surface glycoproteins, the hemagglutinin (HA) which are responsible 
for cell attachment and entry, and the neuraminidase (NA) which are responsible for virus 
release. On the other hand, influenza C virus has one major surface glycoprotein, which is called 
the hemagglutinin-esterase-fusion (HEF) protein that has both the HA and NA functions of 
influenza A and B viruses (Herrler & Klenk, 1991; Vlasak et al., 1989). While influenza A virus 
has many genetically distinct subtypes depending on HA and NA proteins, influenza B virus 
contains two distinguishable lineages which are termed the Victoria lineage and the Yamagata 
lineage (Rota et al., 1990). Influenza A virus infects a wide variety of animals, ranging from wild 
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birds to mammals, including humans, and circulates worldwide causing severe human epidemics 
and pandemics (Webster, 1997). Influenza B virus is also a major pathogen causing human 
influenza epidemics together with influenza A but it does not cause pandemics. Although 
influenza B virus mainly affects humans, it has also been isolated from harbor seals and the 
genome was detected in domestic pigs (Osterhaus et al., 2000; Ran et al., 2015) .  Compared to 
these two influenza viruses, influenza C virus causes mild and asymptomatic disease 
predominantly observed in humans. However, several studies have reported serological evidence 
of influenza C virus infections in dogs and pigs (Manuguerra & Hannoun, 1992; Ohwada et al., 
1987; Youzbashi et al., 1996).  In 2011, a new influenza virus, named influenza D virus, was 
identified from pigs as an influenza C-like virus and was proposed as a new genus in the 
Orthomyxoviridae family (Hause et al., 2014; Hause et al., 2013). Influenza D virus has been 
detected in cattle and pigs in the United States, France and China (Ducatez et al., 2015; Ferguson 
et al., 2015; Hause et al., 2014; Jiang et al., 2014). 
 1.3 Influenza A virus (IAV)     
Influenza A virus (IAV) known as “flu” is the significant respiratory pathogen in humans 
worldwide and causes seasonal epidemics and periodic pandemics. Although wild waterfowl are 
the natural reservoir of IAVs, viruses constantly establish evolutionary changes to adapt to new 
hosts and consequently have been shown to infect many animal species such as domestic birds, 
humans, pigs, horses and dogs (Webster et al., 1992). Due to the susceptibility of a variety of 
animal hosts and continuous adaptation of IAVs, it is difficult to control IAV infections. 
Furthermore, outbreaks of annual epidemics, unpredictable pandemics and zoonotic infections 
pose significant threat to public health.  
3 
IAVs are classified into different subtypes based on the genetic and antigenic properties 
of the two surface glycoproteins HA and NA. To date, 18 HA (H1-H18) and 11 NA (N1-N11) 
subtypes have been identified. Among them, 16 HA subtypes (H1-H16) and 9 NA subtypes (N1-
N9) are circulating in wild birds (Alexander, 2007; Fouchier et al., 2005), while the genome 
sequences of H17, H18, N10 and N11 were recently identified in bats (Tong et al., 2012; Tong et 
al., 2013).   
 1.4 IAV genome organization and proteins 
The genome of IAV is comprised of eight segmented negative-sense RNAs (Palese & 
Schulman, 1976; Ritchey et al., 1976). Each viral RNA (vRNA) segment consists of a 3´end 
non-coding region, an internal coding region, and a 5´end non-coding region. The 3´ and 5´ 
termini of all vRNA segments in IAVs contain highly conserved 12 and 13 terminal nucleotides, 
respectively (Desselberger et al., 1980; Skehel & Hay, 1978). The eight IAV segments are 
numbered from segment 1 to 8 and encode PB2, PB1, PA, HA, NP, NA, M and NS, respectively 
according to the genome size. These eight gene segments can encode up to 18 identified proteins 
(Table 1-1) (Vasin et al., 2014; Yamayoshi et al., 2016).  
 Surface and structural proteins 
IAVs have three surface proteins, including HA, NA and matrix (M1 and M2) proteins. 
IAVs are subtyped based on two glycoproteins, HA and NA, so far 18 different HA and 11 
different NA subtypes have been identified (Tong et al., 2012; Tong et al., 2013). The HA 
glycoprotein performs a critical role during viral entry, serving as the receptor binding and 
membrane fusion protein. The HA protein recognizes the sialic acid (SA) which is bound to 
galactose (Gal) in either α2,3 or α2,6 linkages on the host cell surface. The HA protein has a 
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host-specific recognition based on its affinity to different SA receptors in different species. For 
instance, avian influenza viruses have a preference to recognize α2,3-linked SA, which are 
mainly present in the avian respiratory and intestinal epithelium, while human influenza viruses 
prefer to recognize α2,6-linked SA, which are mostly found in the human respiratory tract 
epithelium (Connor et al., 1994; Naeve et al., 1984; Rogers & Paulson, 1983). During IAV entry, 
the HA protein is cleaved into two subunits, HA1 and HA2 by host extracellular proteases 
(Klenk et al., 1975; Lazarowitz & Choppin, 1975).  This proteolytic cleavage is necessary for 
HA conformational change to enable fusion of the viral and endosomal membranes. Mammalian 
influenza virus and low pathogenic avian influenza viruses generally have a HA cleavage site 
with a Q/E-X-R monobasic motif which is recognized and cleaved by trypsin-like proteases 
produced by respiratory and intestinal epithelia (Kawaoka & Webster, 1988). However, H5 and 
H7 subtypes of avian influenza viruses can possess a polybasic cleavage site with the R-X-R/K-
R motif acquired by insertional mutations and it is recognized and cleaved by the ubiquitous 
furin-like protease (Stieneke-Grober et al., 1992). This specificity of the protease recognition 
determines the virus replication site and pathogenicity in hosts. The viruses possessing a 
monobasic motif at the HA cleavage site are confined to replicate within the respiratory or 
intestinal tract which produce trypsin-like protease, whereas the viruses containing a polybasic 
HA cleavage site can induce systemic replication, which results in the occurrence of highly 
pathogenic avian influenza (Chen et al., 1998; Steinhauer, 1999).      
The NA protein encoded by segment 6 has neuraminidase enzymatic activity which is 
necessary for release and spread of progeny virions from the cells. The NA protein cleaves the 
SAs from host cells to release the newly budded viruses and also removes the SAs from viral 
glycoproteins to avoid the aggregation of virus particles at the release site (Palese et al., 1974). 
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To date, four NA inhibitors have been approved for treatment of IAVs: oseltamivir (F. 
Hoffmann-La Roche, Basel, Switzerland), zanamivir (GlaxoSmithKline, Brentford, UK), 
laninamivir (Daiichi Sankyo Company Ltd, Tokyo, Japan) and peramivir (BioCryst, Durham, 
NC, USA). NA inhibitors bind to the enzyme active site of NA and prevent the release and 
spread of new virus from infected cells (Colman, 1994; McKimm-Breschkin, 2013). The Centers 
for Disease Control (CDC) currently recommend the use of NA inhibitors for the treatment of 
influenza infections (CDC, Influenza antiviral medications: summary for clinicians, May 2016). 
Although NA-specific antibodies are not sufficient to prevent IAV infections, they can inhibit 
viral spread and reduce disease severity (Monto & Kendal, 1973; Schulman et al., 1968). 
Recently, several studies demonstrated that NA antibodies can induce heterologous protection as 
well as long-term immunity against IAVs due to the slower rate of antigenic changes compared 
to HA (Abed et al., 2002; Doyle et al., 2013; Quan et al., 2012; Wan et al., 2015). Therefore, 
some studies have suggested the NA protein as a potential target for influenza vaccines along 
with the HA protein (Bosch et al., 2010; Brett & Johansson, 2005; Kilbourne et al., 2004; 
Wohlbold et al., 2015).     
These two glycoproteins, HA and NA, have complementary functions during viral 
replication. Thus the balance between HA binding affinity and NA sialidase enzymatic activity 
plays a critical role in efficient viral replication and transmission (Gen et al., 2013; Mitnaul et al., 
2000; Wagner et al., 2000). Furthermore, although HA and NA undergo constant evolutionary 
changes, IAVs maintain the HA/NA functional balance to have optimal viral fitness (Gaymard et 
al., 2016; Wagner et al., 2002). 
The matrix 1 (M1) protein encoded in segment 7 is the most abundant protein as well as a 
major structure protein of IAV particles. The M1 protein forms a shell underneath the lipid layer 
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of viral particles and connects the viral ribonucleoprotein (vRNP) with envelope proteins: HA, 
NA and M2 (Elster et al., 1997; Shishkov et al., 1999). The M1 protein plays multiple roles 
during IAV replication cycles. During virus entry, the M1 protein is dissociated from the vRNP 
and allows the release of vRNP to enter the nucleus (Bui et al., 1996; Martin & Helenius, 1991b). 
The newly synthesized M1 protein is transported to the nucleus and interacts with the vRNP and 
the nuclear export protein (NEP), forming a complex which in turn exports from the nucleus to 
cytoplasm (Akarsu et al., 2003; Bucher et al., 1989; Neumann et al., 2000; O'Neill et al., 1998; 
Yasuda et al., 1993). In addition, exported M1, vRNP and NEP protein complex from the 
nucleus inhibit the reentry of vRNP back into the nucleus to promote viral assembly (Martin & 
Helenius, 1991a). During the late stage of viral replication, the M1 protein plays a critical role in 
the processes of viral assembly as well as budding and it influences the viral morphology 
(Burleigh et al., 2005; Elleman & Barclay, 2004; Roberts et al., 1998). In addition to encoding 
the M1 protein, segment 7 of IAV also encodes the matrix 2 (M2) protein via alternative splicing 
(Lamb & Choppin, 1981). During viral entry, the M2 protein works as a proton-selective ion 
channel and allows the proton influx into the virion interior (Chizhmakov et al., 1996; Pinto et 
al., 1992). The low pH of the virion by proton influx triggers the dissociation of the M1 protein 
with the vRNPs as well as the membrane fusion of the viral envelop with the endosomal 
membrane, which leads to the release of the vRNP into the cytoplasm which then migrate into 
the nucleus (Helenius, 1992). The adamantane derivatives, amantadine and rimantadine, are M2 
ion channel blockers and the FDA-approved class of antiviral drugs for IAV infection (Davies et 
al., 1964). They inhibit the M2 ion channel activity to prevent uncoating of IAV as well as the 
release of vRNPs. However, currently the adamantanes are not recommended for treatment of 
IAV infection due to the widespread resistance between human seasonal IAVs and no inhibitory 
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effect on influenza B viruses (Deyde et al., 2007; Gubareva et al., 2010; Hayden & Hay, 1992). 
Since the extracellular domain of M2 (M2e) is a highly conserved between IAVs, it has been a 
target for an universal IAV vaccine even if it induces low protective immunity (De Filette et al., 
2011; Deng et al., 2015; Kim et al., 2014; Neirynck et al., 1999).        
 RNA polymerase complex 
The three largest IAV genome segments 1, 2 and 3 encode three polymerase subunits, 
named polymerase basic protein 2 (PB2), polymerase basic protein 1 (PB1), and polymerse 
acidic protein (PA), respectively. The viral polymerase subunits form the polymerase 
heterotrimeric complex which is an essential complex in the viral replication cycle as it is 
reponsible for the RNA-dependent RNA polymerase activity. The influenza viral ribonucleo-
protein (vRNP) complex is composed of a heterotrimeric polymerase complex and each vRNA 
genome segment which is surrounded by mutilple nucleoproteins (NP). The polymerase 
complexes bind to the short hairpin structure formed from complementary 3´ and 5´ ternimal 
non-coding regions of each vRNA. The PB1 subunit is the centre of the polymerase complex 
containing the conserved motifs for RNA-dependent RNA polymerase activity and is also 
involved in interacting to the the terminal 3´ and 5´ regions of vRNA (Gonzalez & Ortin, 1999; 
Kobayashi et al., 1996; Li et al., 1998). To initiate the transcription process of vRNA, IAV 
polymerse uses a capped primer which is derived from the 5´ end of cellular pre-mRNA by cap-
snatching due to the absence of IAV inherent capping activity (Krug et al., 1979; Plotch et al., 
1979). The PB2 subunit recognizes and binds to host mRNA 5´ cap structures and the PA protein 
cleaves the 5´cap structure of host pre-mRNA by endonucleolytic activity from its N-terminal 
domain (Blaas et al., 1982; Braam et al., 1983; Dias et al., 2009; Plotch et al., 1981). The crystal 
structure analysis revealed the interactions between the C-terminal domain of PA and the N-
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terminal domain of PB1, as well as between the C-terminal domain of PB1 and the N-terminal 
domain of PB2 (He et al., 2008; Sugiyama et al., 2009). Moreover, the crystal structure of the 
vRNP complex shows that the three polymerase subunits form a compact globular structure with 
multiple interactions between them. They are all invovled in the interaction with the RNA 
promoter (Arranz et al., 2012; Coloma et al., 2009; Torreira et al., 2007).  
The NP protein plays a critical role in transcription and replication of viral genes as an 
important structural component of vRNPs and cRNPs. With high affinity to RNA, the NP 
proteins bind to viral RNA genomes to maintain the double helical structures of vRNPs through 
strong interactions between the NP proteins (Yamanaka et al., 1990; Ye et al., 2006).       
 Non-structural proteins 
The non-structural protein 1 (NS1) and nuclear export protein (NEP or NS2) are encoded 
from segment 8 of IAVs. The NS1 protein is the greatly well-known viral antagonist of type I 
interferon (IFN) immune response and a regulator of host gene expression which supports viral 
protein synthesis as well as viral replication. The NS1 protein prevents the IFN response at a pre-
transcriptional level by inhibiting RIG-I activation and the RIG-I signaling pathway, which 
initiates the antiviral response triggered by dsRNAs (Gack et al., 2009; Mibayashi et al., 2007; 
Rajsbaum et al., 2012; Talon et al., 2000; Wang et al., 2000). In addition, the NS1 protein 
inhibits the activation of the interferon-stimulated gene (ISG) products such as the protein kinase 
PKR and the RNAse L-pathway activator OAS at a post-transcriptional level (Lu et al., 1995; 
Min & Krug, 2006; Min et al., 2007). In addition, the NS1 protein contributes to the host shutoff 
activity by preventing splicing of cellular pre-mRNA, cellular polyadenylation machinery as well 
as the export of polyadenylated host mRNAs from the nucleus (Alonso-Caplen & Krug, 1991; 
Alonso-Caplen et al., 1992; Fortes et al., 1994; Nemeroff et al., 1998; Qiu & Krug, 1994). This 
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host shutoff activity of the NS1protein promotes viral gene expression by recruitment of host 
translation-related factors to viral genes while also supporting viral infection by inhibiting the 
IFN-related gene expressions.  
The NEP protein encoded from segment 8 by alternative splicing mediates the export of 
vRNPs from the nucleus by interacting with chromosomal maintenance 1 (Crm1) and the viral 
M1 protein (Akarsu et al., 2003; Elton et al., 2001; Neumann et al., 2000). In addition to the 
nuclear export function, the NEP is involved in the viral budding process by interacting with a 
cellular F1Fo-ATPase (Gorai et al., 2012). Moreover, it has been demonstrated that NEP 
promotes the synthesis of the viral complementary RNP (cRNP) from vRNPs, which 
subsequently leads to the increased production of vRNPs for packaging into the progeny viruses 
(Manz et al., 2012; Robb et al., 2009).  
 Newly discovered proteins 
It was thought that 8 segmented genomic RNAs of IAVs encode 10 viral proteins 
including PB2, PB1, PA, HA, NP, NA, M1, M2, NS1 and NS2. However, since the PB1-F2 
protein was identified in 2001 as the 11
th
 viral protein of IAVs from the PB1gene, seven 
additional viral proteins, PB2-S1, PB1N-40, PA-X, PA-N155, PA-N182, M42 and NS3, have 
been discovered.  
Most recently identified is the PB2-S1 protein which is encoded by following of spliced 
mRNA transcribed from the segment 1, PB2 genome (Yamayoshi et al., 2016). The PB2-S1 
protein localizes to the mitochondria and inhibits the RIG-I-dependent IFN signaling pathway. 
However, the PB2-S1 protein is not essential for virus replication in vitro or for viral 
pathogenicity in vivo (Yamayoshi et al., 2016). The PB1-F2 protein and PB1-N40 proteins are 
expressed from segment 2, PB1 gene of IAVs by an alternative translation initiation process 
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(Chen et al., 2001; Wise et al., 2009). The PB1-F2 protein is considered to be an important 
virulence factor of IAVs. This protein is mainly localized in the mitochondria and reduces 
mitochondrial membrane potential, which is associated with inducing apoptosis as well as 
inhibiting the RIG-I-dependent IFN response (Chen et al., 2001; Conenello et al., 2011; Lowy, 
2003; Varga et al., 2012; Zamarin et al., 2005). The PB1-F2 protein also interacts with the PB1 
protein in the nucleus and regulates polymerase activity (Mazur et al., 2008; McAuley et al., 
2010). Although the PB1-N40 expression is not critical for viral replication and its function still 
remains unclear, the PB1-N40 is obviously associated with both PB1 and PB1-F2 expression, 
which may affect virus replication (Tauber et al., 2012; Wise et al., 2009).   
Segment 3 of IAV genomes encodes not only the PA protein but also three additional PA 
related proteins, PA-X, PA-N155 and PA-N182. The PA-X protein is produced by a +1 
ribosomal frameshift process and contains an identical 191aa N-terminal domain of the PA 
protein along with a PA-X unique 41or 61aa C-terminal domain (Jagger et al., 2012). The PA-X 
protein has a role in host shutoff activity which inhibits host gene expression including 
inflammatory and immune related genes. Thus, the PA-X protein is related with the regulation of 
host immune responses, leading to modulation of viral pathogenicity (Hayashi et al., 2015; 
Jagger et al., 2012). The PA-N155 and PA-N182 are expressed from the 11
th
 and 13
th
 in-frame 
AUG codons, respectively, by alternative translation initiation (Muramoto et al., 2013). Even if 
AUG codons for expression of PA-N155 and PA-N182 proteins are highly conserved and they 
displayed the universal expressions among IAVs, the functions of these proteins have yet to be 
determined (Muramoto et al., 2013). 
The M42 and NS3 proteins are encoded from spliced mRNAs of segment 7, M gene and 
segment 8, NS gene, respectively (Selman et al., 2012; Wise et al., 2012). The M42 protein is 
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able to functionally replace the M2 protein as a proton ion channel, in spite of the different 
sequence from the M2 in the ectodomain (Wise et al., 2012). The NS3 protein is produced as the 
result of a nucleotide substitution in the NS gene, A374G, which is associated with the 
adaptation of avian influenza viruses to mammalian hosts (Selman et al., 2012). However, it is 
still arguable that NS3 expression is associated with host adaptation.       
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Table 1-1 The proteome of influenza A viruses 
Genome 
segment 
Protein mRNA Mechanism of 
expression 
Length
(aa) 
Function 
1 PB2 Segment 1 
non-spliced mRNA 
Translation from AUG1 759 Subunit of the viral polymerase 
complex, binding to host mRNA 5’ 
cap structures 
 
 PB2-S1 Segment 1 
alternatively spliced mRNA 
 
Translation from AUG1 508 Inhibiting RIG-I-dependent IFN 
signaling pathway 
 
2 PB1 Segment 2 
non-spliced mRNA 
Translation from AUG1 757 Subunit of the viral polymerase 
complex, RNA-dependent RNA 
polymerase activity 
 
 PB1-N40 Segment 2 
non-spliced mRNA 
Translation from AUG5 
as the result of leaky 
ribosomal scanning 
 
718 Maintaining the balance between 
PB1 and PB1-F2 expression 
 PB1-F2 Segment 2 
non-spliced mRNA 
Translation from AUG4 
in alternative ORF as 
the result of leaky 
ribosomal scanning 
90a  Virulence factor, Inducing apoptosis, 
Inhibiting RIG-I-dependent IFN 
response, Regulating the polymerase 
activity 
 
3 PA Segment 3 
non-spliced mRNA 
Translation from AUG1 716 Subunit of the viral polymerase 
complex, RNA endonuclease activity 
(cap snatching) 
 
 PA-X Segment 3 
non-spliced mRNA 
Translation from AUG1 
and +1 ribosomal 
frameshifting at codons 
190-193 
 
252a  Host shutoff activity, modulation the 
host response and viral pathogenicity 
 PA-N155 Segment 3 
non-spliced mRNA 
Translation from 
AUG11 as the result of 
leaky ribosomal 
scanning 
 
568 ND 
 PA-N182 Segment 3 
non-spliced mRNA 
Translation from 
AUG13 as the result of 
leaky ribosomal 
scanning 
 
535 ND 
4 HA Segment 4 
non-spliced mRNA 
Translation from AUG1 560 Recognition and binding to receptors 
of target cells, fusion with 
endosomal membrane  
 
5 NP Segment 5 
non-spliced mRNA 
Translation from AUG1 498 Major component of the viral RNP 
complex, encapsidating vRNA 
segments 
 
6 NA Segment 6 
non-spliced mRNA 
Translation from AUG1 465 Sialidase enzymatic activity, 
Cleaving the sialic acids from cells 
to release progeny viruses 
 
7 M1 Segment 7 
non-spliced mRNA 
Translation from AUG1 252 Main component of the viral 
membrane, multiple roles in virion 
assembly and infection 
 
 M2 Segment 7 
alternatively spliced mRNA 
Translation from AUG1 97 Membrane protein, forming proton 
ion channels for the proton influx 
which triggers the release of vRNPs 
13 
 
 M42 Segment 7 
alternatively spliced mRNA 
Translation from AUG2 99 Functionally replacing the M2 ion 
channel 
 
8 NS1 Segment 8 
non-spliced mRNA 
Translation from AUG1 217 Evasion of host immune response, 
host shutoff activity 
 
 NS2(NEP) Segment 8 
alternatively spliced mRNA 
Translation from AUG1 121 Mediating vRNP export from 
nucleus to the cytoplasm 
 
 NS3 Segment 8 
alternatively spliced mRNA 
Translation from AUG1 174 ND 
a
 : can be truncated in some viral strains. 
ND : Functions have not been determined. 
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 1.5 IAV replication cycle  
The IAV replication cycle is initiated by the attachment of virus particles to cellular 
receptors (Figure 1-1). The HA protein of IAVs recognizes and binds to SA containing 
glycolipids or glycoproteins on the cell surface such as α2,3-linked SA or α2,6-linked SA, which 
determines the host and tissue specificity of IAVs (Baum & Paulson, 1990; Couceiro et al., 1993; 
Rogers & Paulson, 1983). Once a virus particle binds to the cellular receptor, the virus is 
internalized by either clathrin-dependent or clathrin-independent endocytosis such as 
micropinocytosis (de Vries et al., 2011; Matlin et al., 1981; Sieczkarski & Whittaker, 2002) . 
Inside the endosome, the highly acidic conditions trigger several changes in the virion. First, the 
viral M2 ion channel allows an influx of proton ions into the interior of the viral particle and 
increased acidity within the virion causes dissociation of vRNPs from the M1 protein (Bui et al., 
1996; Pinto et al., 1992). Next, the acidic condition of the late endosome promotes a 
conformational change in the HA protein that leads to the fusion of the viral envelope with the 
endosomal membrane and finally, vRNPs are released from the virion into the cytoplasm 
(Helenius, 1992; Skehel & Wiley, 2000). The vRNPs subsequently enter the cellular nucleus, 
where vRNA replication and transcription occur by the RNA-dependent RNA polymerase 
complex (Krug et al., 1987). During this process, four different RNA species are produced, 
including viral mRNA, positive-sense complementary RNA (cRNA), negative-sense viral 
genomic RNA (vRNA) and negative-sense small viral RNA (svRNA) (Etkind et al., 1977; 
Jackson et al., 1982; Perez et al., 2010; Plotch & Krug, 1978; Scholtissek & Rott, 1963) . The 
viral RNA polymerase produces cRNA through copying of the vRNA and in turn cRNA serves 
as a template to synthesize more vRNAs. Synthesized cRNA and vRNA associate with the 
heterotrimeric polymerase complex and multiple NP proteins to form cRNP and vRNP. The 
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svRNA consists of 22-27 nucleotides which correspond to the 5´ end of each of the vRNA 
genomes. During viral replication, svRNA is thought to act in concert with NEP as an important 
regulator to promote cRNA synthesis over mRNA transcription, which consequently results in 
additional production of new vRNAs (Perez et al., 2010; Umbach et al., 2010). Viral mRNA has 
a 5´ cap which is obtained from cellular mRNA through cap-snatching and has 3´ poly-A tail 
(Dias et al., 2009; Krug et al., 1979; Luo et al., 1991; Plotch et al., 1979; Zheng et al., 1999). 
Viral mRNAs are transported to the cytoplasm for viral protein synthesis using the cellular 
translation machinery (Compans, 1973; Garfinkel & Katze, 1993). Newly synthesized PB2, PB1, 
PA, NP, NEP, NS1 and M1 proteins, which are necessary for vRNA transcription and replication, 
are imported back into the nucleus. Imported new polymerase subunits (PB2, PB1 and PA) and 
NP proteins bind to newly produced vRNAs or cRNAs to assemble vRNPs and cRNPs, 
respectively. These newly assembled vRNPs are exported to the cytoplasm through its 
interacting with NEP, M1 as well as cellular nuclear export machinery (Bui et al., 2000; Chase et 
al., 2011; Elton et al., 2001; O'Neill et al., 1998). Exported vRNPs migrate to the plasma 
membrane across the cytoplasm, mediated by Rab11-containing structures (Eisfeld et al., 2011). 
At the late time points of infection, vRNPs and viral proteins enrich at the apical plasma 
membrane followed by the virion assembly and budding process. The RNA packaging signals 
which are located in the 5´ and 3´ terminal regions of each vRNA, including both non-coding 
and partial coding sequences, are required to bring each of the eight segments into every virion 
(Chou et al., 2012; Fujii et al., 2003; Goto et al., 2013). To assemble new virus particles, HA, 
NA, M1, M2 and vRNPs interact with each other and these interactions promote the budding of 
progeny virions (Rossman & Lamb, 2011). Viral M1, M2 and NEP proteins as well as host 
factors such as ATP, F1Fo-ATPase, actin filaments, G-protein and kinase activity are known to 
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be required for virus particle budding (Demirov et al., 2012; Gorai et al., 2012; Hui & Nayak, 
2001; 2002; Rossman et al., 2010). Once virions are assembled and bud out on the cell 
membrane, neuraminidase activity of the NA protein cleaves the link between the HA protein 
and SA molecules to release progeny virus particles from the cell surface (Palese et al., 1974).     
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Figure 1-1 Influenza A virus replication cycle 
 
Figure 1-1 The IAV replication cycle is initiated by the attachment of viral HA protein to cellular 
receptors. Once virus particle binds to the cellular receptor, the virus is internalized by either 
endocytosis or micropinocytosis. The acidic condition of the endosome causes dissociation of 
vRNPs from the M1 protein and promotes a conformational change in the HA protein that leads to 
the fusion of the viral envelope with the endosomal membrane and finally, vRNPs are released 
from the virion into the cytoplasm. The vRNPs subsequently enter the nucleus, where vRNA 
replication and transcription occur by the RNA-dependent RNA polymerase complex. Viral 
mRNAs are transported to the cytoplasm for viral protein synthesis using the cellular translational 
machinery. Newly synthesized PB2, PB1, PA, NP, NEP, NS1 and M1 proteins which are 
necessary for vRNA transcription and replication are imported back into the nucleus. Newly 
assembled vRNPs are exported to the cytoplasm through its interacting with NEP, M1 as well as 
cellular nuclear export machinery. Exported vRNPs migrate to the plasma membrane across the 
cytoplasm. At the late time points of infection, vRNPs and viral proteins enrich at the apical 
plasma membrane followed by the virion assembly and budding process. (Adapted from Te 
Velthuis & Fodor, Nature Reviews Microbiology, 2016, doi: 10.1038/nrmicro.2016.87) (Te 
Velthuis & Fodor, 2016)  
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       1.6 IAV hosts 
It is known that the natural reservoirs of IAVs are wild waterfowl as well as shorebirds, 
and 16 HA and 9 NA subtypes are detected from wild aquatic birds (Webster et al., 1992). 
Recently, there is growing evidence that bats are the possible reservoir of IAVs with finding two 
HA and two NA new subtypes from bats (Ma et al., 2015; Tong et al., 2012; Tong et al., 2013). 
IAVs in domestic birds and mammals have evolved either indirectly or directly from avian 
influenza viruses (AIVs) in wild aquatic bird reservoirs (Webster et al., 1992).  
 Avian hosts 
 Wild aquatic birds, especially Anseriformes (ducks, geese and swans) and 
Charadriiformes (shorebirds, gulls and alcids), are the primary reservoirs of IAVs. Although 
IAVs have been detected from over 100 wild birds, dabbling ducks and especially mallards are 
considered to be the major sources of IAVs in wild aquatic birds (Krauss et al., 2004; Munster et 
al., 2007; Olsen et al., 2006).  In aquatic birds, IAVs mainly replicate in the intestinal tract which 
are then shed in feces and spread by fecal-oral route through contaminated water, while some 
subtypes such as H3 and H4 can also replicate well in the respiratory tract (Bahl et al., 2013; 
Runstadler et al., 2013; Webster et al., 1992). The migratory wild birds play a critical role in the 
wide geographic spread and initial introduction of IAVs. In 2014, highly pathogenic (HP) H5N8 
avian influenza viruses were introduced into North America from Asia by migratory wild birds 
which then led to reassortment with the North American lineage resulting in a generation of new 
H5N1 and H5N2 genotypes (Claes et al., 2016; Jhung & Nelson, 2015). IAVs in natural 
reservoirs display limited evolution. An interpretation is that the continued mutations do not 
provide additional advantages to IAVs that is already well established within natural reservoirs 
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(Webster et al., 1992). However, to transmit to other host species from avian, IAVs show rapid 
mutations as well as the evolution required for adaptation to new hosts.        
  Since transmission of IAVs from wild birds to domestic birds occurs commonly in 
ponds or backyard poultry farms, domestic ducks as well as geese may act as intermediate bridge 
hosts to transmit IAVs to terrestrial poultry. Most AIVs cause an asymptomatic or mild disease 
in domestic birds as the low pathogenic avian influenza viruses (LPAIVs) and H1, H3, H5, H6, 
H7 and H9 subtypes are most frequently isolated from them (Alexander, 2007; Peiris & Yen, 
2014). On the other hand, two subtypes of AIVs including H5 and H7 can evolve into highly 
pathogenic avian influenza viruses (HPAIVs), causing severe disease with up to 100% mortality 
in domestic poultry. The live poultry markets have been described to have a variety of IAV 
subtypes and provide ideal conditions for genetic mixing of IAVs as well as generation of new 
recombinant viruses. In addition, the live poultry market is a major source of interspecies 
transmission events for IAVs and range from domestic poultry to mammals, including humans 
through close contact (Pepin et al., 2013b). Including a recent outbreak of  the H7N9 subtype in 
China, many human cases of AIV infections with H5N1, H5N6, H9N2 and H10N8 from live 
poultry markets have been reported (Bi et al., 2015; Liu et al., 2015a; Peiris et al., 1999; Pepin et 
al., 2013a; Wu & Gao, 2013).  
 Mammalian hosts 
Over twenty mammalian species, including humans, dogs, horses and pigs, which have  
established a stable infection chain, and other accidental hosts without stable infection such as 
cats as well as sea mammals can be infected with IAVs (Webster et al., 1992). Although some 
AIVs can infect mammalian hosts without prior adaptation, either gene reassortment or genetic 
mutations are generally required to achieve the interspecies transmission and adaptation of IAVs 
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from avian to mammalian hosts. We will discuss the molecular determinants of mammalian 
adaptation further in Chapter 1.10.  In humans, only three subtypes of IAVs, H1N1, H2N2 and 
H3N2, have been determined to be the stable lineages which have caused annual epidemics or 
occasional pandemics. More detailed information about human influenza virus will be discussed 
in Chapter 1.8. 
Swine are thought to be an important host of IAVs because they can be infected with both 
mammalian and avian influenza viruses to generate novel reassortant IAVs which can infect 
other mammalian hosts and possess a potential threat to humans. This was highlighted by the 
swine-origin 2009 H1N1 pandemic (pH1N1) in humans as well as more recent human infections 
with a novel H3N2 variant virus which is a reassortant between 2009 pandemic H1N1 (pH1N1) 
and TR H3N2 SIV (Dawood et al., 2009; Epperson et al., 2013; Peiris et al., 2009). Swine 
influenza was first reported in pigs associated with the 1918 Spanish H1N1 pandemic in humans 
and the virus was subsequently identified in 1930 as an H1N1 IAV (Shope, 1931). Swine 
influenza is an important respiratory disease and causes a continuous problem in swine 
populations throughout the world. Infected pigs show from asymptomatic to fatal conditions 
depending on the virus strain and co-infection of other pathogens. Although only limited 
subtypes of IAVs including H1N1, H1N2 and H3N2 are established as endemic viruses in pigs, 
multiple lineages and genotypes of swine influenza viruses (SIVs) are circulating in different 
continents and regions of the world (Vincent et al., 2014). In North America, classical swine 
H1N1 (cH1N1) virus which evolved from the 1918 H1N1 pandemic, was circulating in swine 
population until late 1990s. In 1998, a novel triple-reassortant (TR) H3N2 virus emerged and 
rapidly adapted to the swine population. This TR H3N2 virus contains PB2 and PA genes 
derived from AIV, PB1, HA and NA genes from human IAV, and NP, M and NS genes from 
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cH1N1 swine IAV (Zhou et al., 2000). After that, TR H3N2 viruses reassorted with cH1N1 SIVs 
as well as human seasonal H1N1 viruses, subsequently generating multiple reassortant viruses 
which retain a triple reassortant internal gene cassette (TRIG) consisting of human (PB1), avian 
(PB2 and PA) and classical swine (M, NP and NS) IAV origins (Ma et al., 2009; Vincent et al., 
2008). Since the 2009 pH1N1 virus was introduced into pigs, reassortant viruses between the 
2009 pH1N1 and the endemic SIVs have been circulating in US swine and notably, the TRIG M 
segment was replaced by the Eurasian swine M gene (Nelson et al., 2015; Nelson et al., 2012). 
In Europe, the Eurasian avian-like H1N1, human-like H3N2, and human-like H1N2 lineages 
have emerged. In the late 1970s, cH1N1 SIV was replaced by avian-like H1N1 virus which has 
become the dominant swine strain in many European countries (Pensaert et al., 1981). After the 
1968 human H3N2 pandemic, human-like H3N2 viruses were detected in swine followed by 
reassortment with the avian-like H1N1 SIVs in the 1980s (Castrucci et al., 1993). In 1994, a new 
reassortant H1N2 virus containing genes from human H1N1 virus and H3N2 SIV, was detected 
in Great Britain and in turn became widespread in other European countries (Brown et al., 1995; 
Kyriakis et al., 2011). Following the outbreak of the 2009 pH1N1 virus, co-circulation of 2009 
pH1N1 with the endemic European SIVs in swine herds led to generation of several reassortant 
viruses (Howard et al., 2011; Moreno et al., 2011). In Asia, nearly 60% of world’s pork 
production is produced and diverse variants of IAVs are co-circulating in the swine population. 
The cH1N1 SIVs were first detected in China in 1974, becoming enzootic in swine in many 
Asian countries, including China, Japan, Thailand and Vietnam. In China, H1N2 virus 
containing  the human origin N2 segment co-circulated with cH1N1 SIVs and H3N2 human 
IAVs were occasionally transmitted to swine (Peiris et al., 2001; Shortridge et al., 1977). In 
addition, the H1N1 AIVs which are independent of Eurasian avian-like H1N1 viruses were 
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detected in 1993 in China (Guan et al., 1996). With the enhanced intercontinental movement of 
pigs, diverse SIVs were introduced and co-circulated in swine of Asian countries, which led to 
genetic diversity of SIVs in Asia. For example, the European H1N1 as well as H3N2 SIVs were 
found in 1999 and 2001, respectively and the North American TR SIVs were first isolated in 
China in 2002 (Vijaykrishna et al., 2011). Recently, the 2009 pH1N1 virus and its reassortant 
viruses with endemic SIVs have been detected in swine in many Asian countries (Vijaykrishna et 
al., 2010). Furthermore, several AIVs such as H9N2, H5N1, H4N8 and H6N6 have been 
sporadically reported in the swine of a few Asian countries (Su et al., 2012; Trevennec et al., 
2011; Xu et al., 2004a; Zhang et al., 2011).                      
Until now, two different equine IAVs, H7N7 and H3N8 are known to cause considerable 
respiratory disease in the horse population (Sovinova et al., 1958; Waddell et al., 1963). The 
H7N7 subtype has not been reported in over three decades and is considered to be extinct in 
equine (Cullinane et al., 2010) . However, equine H7N7 subtype has been studied for its 
potential virulence in other mammalian hosts, since the H7N7 lineage contains the HPAIV 
feature, a multi-basic cleavage site in its HA protein and displaying high virulence in mice 
without prior adaptation (Gibson et al., 1992; Kawaoka, 1991; Murcia et al., 2010). Since the 
1970s, H3N8 equine virus has been circulating in the equine population worldwide (Daly et al., 
1996). This H3N8 subtype has also been reported to cross the species barrier and transmit to 
dogs as well as pigs (Crawford et al., 2005; Tu et al., 2009).     
Since 2004, two stable circulating IAV strains, H3N8 and H3N2, have been described in 
canines. The H3N8 influenza virus which is derived from equine was first isolated in 2004 and 
caused respiratory disease in dogs (Crawford et al., 2005). Avian-origin H3N2 canine IAV has 
been detected, generating reassortant viruses with other IAVs such as H5N1 and H1N1 (Lee et 
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al., 2009; Li et al., 2010; Song et al., 2012; Zhu et al., 2015). Serological data indicated that 
dogs can be infected with the 2009 pH1N1 virus and transmission of pH1N1 virus can also occur 
between dogs (Dundon et al., 2010). Although there are no known IAVs which are established 
and stably circulate in cats, several cat infection cases with different IAVs have occurred. These 
include human-origin H2N2, H3N2, H1N1 including the 2009 pH1N1 virus, avian-origin H7N3 
and HP H5N1 virus (Hinshaw et al., 1981; Kuiken et al., 2004; McCullers et al., 2011; Romvary 
et al., 1975; Songserm et al., 2006; Sponseller et al., 2010) .  
Sporadic IAV isolations from marine mammals have been reported. In 1980, H7N7 IAV 
was isolated from dead seals and later, H4N5, H4N6 and H3N3 IAVs outbreaks were also 
observed in seals (Callan et al., 1995; Geraci et al., 1982; Webster et al., 1981). In 1984, H13N2 
as well as H13N9 subtypes were detected from a pilot whale (Hinshaw et al., 1986). Recently, 
the 2009 pH1N1 virus was detected from an elephant seal in 2010 and H3N8 IAV of avian origin 
was isolated from Atlantic harbor seals in 2011 (Anthony et al., 2012; Goldstein et al., 2013).       
 The mixing vessels 
The HA proteins of IAVs bind to sialic acids (SAs) which are linked to galactose with 
either α2,3 or α2,6 linkage on the host cell surface. Differnet HA proteins have different 
specificities for recognition of these receptors and the expression of specific SAs on cell surfaces 
varies between different tissues and host species. Most human IAVs preferentially bind to α2,6-
linked SAs while avian and equine IAVs recognize α2,3-linked SAs (Connor et al., 1994). To 
achieve the interspecies transmission of IAVs, a switch in receptor preference of HA proteins is 
necessary to target new host species. Therefore, IAVs overcome host barriers by rapid evolving 
through either gene reassortments or genetic substitutions. The “mixing vessel” theory explains 
the mechanism that simultaneous infection of one host with avian- and human-like viruses can 
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generate the novel reassortant viruses which might be able to transmit from avian hosts to 
humans (Ito et al., 1998; Scholtissek et al., 1985). Pigs are susceptible to both avian- and human-
like IAVs due to the distribution of both α2,3- and α2,6-linked SAs in the cells lining the pig 
respiratory tracts. Therefore, pigs are widely known as a mixing vessel of IAVs and generate the 
avian/human/swine reassortants which can obtain the preference to recognize human virus 
receptors and infect humans. The most notable example is the emergence of the swine-origin 
2009 pH1N1 virus that caused a recent pandemic in humans. This virus was generated by 
reassortment between the North American TR H3N2 or H1N2 swine viruses and the Eurasian 
avian-like H1N1 SIVs (Smith et al., 2009b). Other animal species also express both α2,3- and 
α2,6-linked SAs receptors suggesting the possibility of  acting as the mixing vessel for IAVs. For 
example, domestic poultry species, such as quails and turkeys possess both avian- and human-
type receptors in the intestinal and respiratory tract, while wild waterfowls carry predominantly 
α2,3-linked SAs (Costa et al., 2012; Gambaryan et al., 2002; Pillai et al., 2010). In fact, several 
well established AIVs in poultry such as the H9N2, HP H5N1 and H7 subtypes have been shown 
to have an increased affinity to α2,6-linked SAs receptors compared to other AIVs, while also 
having the capability to transmit to mammals, including humans (de Wit et al., 2010; Li et al., 
2014; Xiong et al., 2014). In addition, several studies demonstrated the possibility of both quails 
and turkeys as being mixing vessels (Cilloni et al., 2010; Giannecchini et al., 2010; Pillai et al., 
2010; Thontiravong et al., 2012). The respiratory tract of both dogs and cats express both α2,3- 
and α2,6-linked SAs receptors, indicating their potential as intermediate hosts for IAVs (Lin et 
al., 2012; Wang et al., 2013; Zhang et al., 2013a).           
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 1.7 IAV evolution 
IAV evolution by different mechanisms is related with changing antigenicity and viral 
adaptation to the new species. Two major mechanisms which are involved in IAV evolution are 
antigenic drift and antigenic shift.   
 Antigenic drift 
Antigenic drift refers to the genetic mutation which results in amino acid substitutions 
(Smith et al., 1951). The RNA-dependent RNA polymerase of IAV has an error prone nature by 
lack of a proof reading process during viral replication. Lack of proof-reading results in very 
high IAV mutation rates, nearly from 1×10
-3
 to 8×10
-3
 substitutions per base pair per year (Chen 
& Holmes, 2006). The HA and NA surface glycoproteins are associated with inducing the host’s 
neutralizing antibodies to block viral infection. Therefore, mutations which change the amino 
acid composition in the antigenic sites of HA and NA proteins may permit IAVs to escape from 
the preexisting host immunity with different antigenic properties and also provide selective 
advantages for these viruses to emerge as a novel seasonal epidemic strain (Both et al., 1983). 
Thus, antigenic drift is the reason why the annual influenza vaccine composition needs to be 
reviewed and updated every year to keep up with evolving IAVs. In addition, this mutation 
allows IAVs to establish the antiviral drug resistances which have been observed in various IAV 
strains (de Jong et al., 2005; Lackenby et al., 2008; McKimm-Breschkin, 2000).     
 Antigenic shift 
The eight segmented RNAs of IAVs allow shuffling of gene segments when two or more 
IAVs co-infect one host cell, which leads to the generation of novel reassortant viruses 
containing genes from both parental viruses. In particular, antigenic shift is able to produce new 
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subtypes of IAVs by introducing new HA and/or NA genes from other IAVs (Kilbourne, 1969; 
Muramoto et al., 2006). These new IAV subtypes are responsible for emerging pandemics when 
most human populations do not have protective immunity to the novel IAVs (Garten et al., 2009; 
Scholtissek et al., 1978a).  
 1.8 IAV epidemics and pandemics 
IAVs are the main cause of seasonal epidemics and occasional pandemics. To date, only 
three IAV subtypes, H1N1, H2N2 and H3N2 have caused pandemics while H1N1 and H3N2 
subtypes are currently circulating to cause seasonal epidemics in humans.  
 Seasonal epidemics 
Since 1977, two seasonal epidemic viruses (H1N1 and H3N2) have been co-circulating 
with frequent reassortment between these subtypes in humans (Holmes et al., 2005; Nelson et 
al., 2008). The annual epidemics generally affect 10-20% of the population and are estimated to 
lead to approximately 3 to 5 million cases of severe infections as well as 250,000 to 500,000 
deaths worldwide (WHO, 2014) and 200,000 hospitalizations with up to 49,000 deaths in the 
United State (CDC, 2010). The influenza epidemics mainly occur during wintertime with dry 
and cold conditions which appear to support efficient IAV transmission and spread (Lowen et 
al., 2007).  
 1918 Spanish H1N1 pandemic 
The Spanish influenza pandemic caused by the H1N1 virus is known to be the most lethal 
pandemic in human history. This pandemic affected hundreds of millions and killed 
approximately 50 million people worldwide (Johnson & Mueller, 2002). An unusual mortality 
pattern was seen during the 1918 pandemic, presenting a high mortality rate among young aged 
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adults between 15-34 years old (Glezen, 1996).  Although several studies suggested that the 1918 
pandemic virus evolved from avian viruses or mammalian hosts, its origin is still undetermined 
(Smith et al., 2009a; Taubenberger, 2006). The complete genomes of 1918 influenza virus were 
sequenced from fixed and frozen lung samples from infected patients (Taubenberger et al., 
1997). Moreover, reconstruction of this virus using reverse genetics revealed more information 
regarding the pathogenesis and genetic features of 1918 pandemic influenza virus (Kash et al., 
2006; Kobasa et al., 2007; Tumpey et al., 2005a; Tumpey et al., 2007; Weingartl et al., 2009).  
 1957 Asian H2N2 pandemic 
In 1957, a new pandemic H2N2 influenza virus emerged in China and spread to East Asia, 
North America and Europe. Previously circulating H1N1 human virus which was derived from 
1918 pandemic virus was replaced by the new pandemic H2N2 virus. This Asian H2N2 
pandemic virus was generated by reassortment between circulating human H1N1 virus and avian 
H2N2 virus: HA, NA and PB1 genes from avian virus and the remaining genes from human 
virus (Kawaoka et al., 1989; Scholtissek et al., 1978a). By 1958, its circulation caused 2 million 
deaths worldwide including 70,000 deaths in the United States (Kilbourne, 2006). 
 1968 Hong Kong H3N2 pandemic 
The Hong Kong H3N2 virus emerged in 1968 and replaced the circulating H2N2 virus. 
The pandemic H3N2 virus was also the consequence of reassortment between human and avian 
viruses. Circulating H2N2 virus acquired the new HA and PB1 gene from avian H3 virus and 
generated the new reassortant H3N2 virus. Until 1970, approximately one million people died 
globally and about 34,000 people were killed in the United States by the Hong Kong H3N2 
pandemic influenza (Kilbourne, 2006). 
28 
 1977 Russian H1N1 influenza 
In 1977, H1N1 influenza virus reoccurred in the Russian-Chinese border region affecting 
young adults under 23 years old. The recurrent H1N1 virus had high genetic similarity to 
previous H1N1 viruses which circulated in the early 1950s before the H2N2 outbreak (Nakajima 
et al., 1978; Scholtissek et al., 1978b) . With regards to the lack of genetic evolution in 
comparison with the H1N1 virus in 1950s, it is assumed that the 1977 H1N1 virus was an 
unexpected release from a research lab. The reemerged H1N1 virus co-circulated with H3N2 
viruses instead of replacing them and in turn these two viruses continue to circulate together in 
humans to date (Rambaut et al., 2008).  
 2009 H1N1 pandemic 
The first influenza pandemic of the 21
st
 century was caused by a novel reassortant H1N1 
virus of swine origin which spread to worldwide in 2009 (Dawood et al., 2009; Peiris et al., 
2009). Since 2009 pH1N1 virus was antigenically similar to previously circulating H1N1 viruses 
prior to 1957, it mainly affected young or middle-aged adults who didn’t have prior immunity, 
while the elderly in 33% of those aged over 60 years had cross-protective immunity established 
from previous exposure to H1N1 virus before 1957 or by H1N1 influenza vaccination in 1976 
(Hancock et al., 2009). This 2009 pH1N1 virus affected more than 214 countries and territories 
resulting in hundreds of millions infection cases including over 18,000 deaths throughout the 
world by August 2010 (WHO, 2010).  
Genetic analysis indicated that 2009 pH1N1 virus was generated by the reassortment 
between triple-reassortant H3N2 swine virus harboring human, avian and swine origin gene 
segments, classical H1N1 swine virus and Eurasian avian-like H1N1 swine virus (Smith et al., 
2009b). The PB2 and PA segments were contributed by North American avian viruses, while the 
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PB1 gene was from the human H3N2 virus. The HA, NP and NS segments originated from 
classical swine viruses while the other segments, NA and M, were from the Eurasian avian-like 
swine viruses (Figure 1-2). It is thought that the ancestor of pH1N1 virus was circulating in 
swine populations without symptoms for more than 10 years before transmission to humans and 
the 2009 outbreak (Mena et al., 2016; Smith et al., 2009b). Previous studies with several animal 
models including mice, pigs, ferrets and non-human primates indicated that 2009 pH1N1 strain 
is more pathogenic in these animal models compared with seasonal H1N1 strains (Itoh et al., 
2009; Maines et al., 2009; Munster et al., 2009; Perez et al., 2009). Recently, this pandemic 
virus replaced the previous seasonal H1N1 strains and stably co-circulates with seasonal H3N2 
viruses in humans. Additionally reassortant viruses between 2009 pH1N1 and human H3N2 
viruses have also been detected (Lee et al., 2010; Liu et al., 2010; Myers et al., 2011; Rith et al., 
2015) .      
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Figure 1-2 Origin of 2009 pandemic H1N1  
Figure 1-2 2009 pH1N1 virus was generated from the reassortment of triple-reassortant H3N2 
swine virus harboring human, avian and swine origin gene segments, classical H1N1 swine virus 
and Eurasian avian-like H1N1 swine virus. Each gene segments of human, avian, or swine origin 
corresponds to a characteristic feature above the schematic viral particles.    
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 Pandemic potential 
In humans, only three HA subtypes of IAVs (H1, H2 and H3) caused pandemics and 
have established the ability of efficient human-to-human transmission. However, some other 
influenza subtypes such as H5, H6, H7, H9 and H10 have been reported to be able to cross the 
species barrier to infect humans which has raised  concerns (Arzey et al., 2012; Ostrowsky et al., 
2012; Peiris et al., 1999; Subbarao et al., 1998; Yuan et al., 2013; Zhang et al., 2014). 
The first zoonotic case of HPAI H5N1 virus human infections through direct exposure to 
infected birds was reported in Hong Kong in 1997 and resulted in 6 deaths out of 18 infection 
cases (de Jong et al., 1997). Since 2003, severe HPAI H5N1 outbreaks have been reported in 
Asia, Europe and Africa with occasional human infections. As of October 2016, over 850 cases 
of HPAI H5N1 infections in humans have been confirmed, of which 452 were fatal (WHO, 
2016a). Although the HPAI H5N1 virus has limited human-to-human transmission, it is possible 
that evolutionary changes to the H5N1 virus and reassortment with current human IAVs may 
lead to better adaptation of avian H5N1 virus to humans, which give rise to significant pandemic 
threats.  
Several H7 subtypes of avian influenza viruses have infected humans with some fatal 
cases (Belser et al., 2009). In 2003, HPAI H7N7 virus emerged in the Netherlands, causing 89 
human cases with one fatality (Fouchier et al., 2004). In addition, there were three human 
infection cases of poultry workers with HPAI H7N7 virus in Italy in 2013 (Bonfanti et al., 2014; 
Puzelli et al., 2014). Interestingly, these H7N7 viruses usually induced conjunctivitis in humans, 
whereas they were highly virulent to poultry (Bonfanti et al., 2014; Fouchier et al., 2004; Puzelli 
et al., 2014).  In 2013, a novel LPAI H7N9 virus of avian origin emerged in China and human 
infection cases are still being reported (Gao et al., 2013c; Husain, 2014; Liu et al., 2015b). In 
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humans, this H7N9 virus has caused severe pneumonia as well as acute respiratory distress 
syndrome, while only mild or no symptoms are observed in poultry (Gao et al., 2013a). As of 
August 2016, there have been 859 laboratory-confirmed human cases of H7N9 infection 
including 315 deaths according to the WHO (WHO, 2016b). The outbreaks of H7 subtypes have 
been reported in poultry along with occasional human infections resulting in serious disease, 
increasing the consideration of pandemic potential risks (Lopez-Martinez et al., 2013; Ostrowsky 
et al., 2012; Skowronski et al., 2006; Tanner et al., 2015; Tweed et al., 2004).  
LPAI H9N2 viruses have been widely circulating in domestic birds and have become 
endemic in many Eurasian countries (Alexander, 2003; 2007). Numerous recently emerged avian 
influenza viruses, such as the H5N1, H7N9, H10N8 and H5N2 subtypes are produced by 
reassortment between other subtype precursor viruses from wild birds and widespread H9N2 
viruses (Guan et al., 1999; Liu et al., 2015a; Pu et al., 2015; Xu et al., 2015). Reassortment with 
H9N2 viruses gives rise to the ability of wild-bird avian influenza viruses to infect domestic 
birds and humans more efficiently. Importantly, H9N2 virus and its reassortants have 
sporadically caused infections in pigs as well as humans with several fatal cases (Gao et al., 
2013c; Liu et al., 2014; Yu et al., 2008; Yu et al., 2011; Zhang et al., 2014). Thus, we cannot 
exclude the possibility that reassortment events between H9N2 virus, human and other influenza 
viruses may generate new viruses with pandemic potential.    
Since the outbreak of 2009 pH1N1 in humans, transmission of pH1N1 virus from humans 
to swine called reverse zoonosis has been observed around the world (Charoenvisal et al., 2013; 
Harder et al., 2013; Howden et al., 2009; Keenliside, 2013; Nagarajan et al., 2010; Zhao et al., 
2012). Since 2009, the pH1N1 virus has been maintained in the swine population and 
subsequently reassorted with circulating triple-reassortant H1N1 and H3N2 swine viruses to 
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generate novel genotype of viruses (Ali et al., 2012; Ducatez et al., 2011; Liu et al., 2012; 
Vijaykrishna et al., 2010). Notably, the novel generated reassortant H1N2 and H3N2 variant 
viruses, known as H1N2v and H3N2v, have been reported to infect humans (Epperson et al., 
2013; Komadina et al., 2014). In particular, H3N2v which contains the M gene from 2009 
pH1N1 virus was first isolated in human in 2011 and there have been over 350 confirmed cases 
of human infection with H3N2v viruses including one death reported in USA according to CDC 
report, as of September 2016 (CDC, 2016; Jhung et al., 2013; Nelson et al., 2012). Although the 
H3N2v viruses have displayed limited human-to-human infection, this virus is antigenically 
distinct from recently circulating H3N2 human seasonal viruses and has raised the potential risk 
of a large number of human infections due to the lack of cross-protective immunity. Moreover, 
with increasing reverse zoonosis events, novel reassortant viruses may increase adaptation and 
transmissibility among humans.    
 1.9 Host response to IAV 
The host responses play critical roles to protect the host from IAV infection. The innate 
and adaptive immune responses are the major host defense mechanism against virus infections. 
However, unbalanced and excessive immune responses to IAV infection cause 
immunopathology by inducing severe lung damage, respiratory failure and fatal pneumonia. 
Therefore, an appropriate host response is important to protect the host efficiently.     
 Innate and adaptive immunity 
The first line of defense against IAV infection is the mucus and collectin barriers 
covering respiratory epithelial cells to prevent viral binding and invading to cells. If IAVs 
successfully overcome these barriers and start replication in cells, rapid innate cellular defenses 
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are induced to control virus replication. The IAV infection is recognized by pattern-recognition 
receptors (PRRs), such as Toll-like receptor (TLR) 3/7 and retinoic acid-inducible gene-I (RIG-I) 
through detection of the viral double-strand or single-strand RNAs (Diebold et al., 2004; Le 
Goffic et al., 2007; Pichlmair et al., 2006).  The initiated signaling pathways of PRRs induce the 
production of type I as well as type III IFNs and activate antiviral immune responses (Garcia-
Sastre, 2011). During IAV infections, IFNs are mainly produced by respiratory epithelial cells, 
macrophages and plasmacytoid dendritic cells (pDCs) (Cheung et al., 2002; Hogner et al., 2013; 
Jewell et al., 2007). The secretion of IFNs leads to the expression of hundreds of different 
interferon-stimulated genes (ISGs) which establish the antiviral activity to inhibit virus 
replication efficiently (Randall & Goodbourn, 2008). Several ISGs, including Mx family, viperin 
and IFN-induced transmembrane (IFITM) family have been shown to have the direct anti-
influenza activity (Brass et al., 2009; Pavlovic et al., 1992; Wang et al., 2007; Zimmermann et 
al., 2011). In addition to the IFN responses, PRRs induce the release of pro-inflammatory 
cytokines and chemokines by cells of the innate immune system. These pro-inflammatory 
cytokines and chemokines are responsible for the recruitment of immune cells, such as 
neutrophils, natural killer (NK) cells and monocytes, to the virus infected site and in turn, 
activate the adaptive immune response by development and modulation of virus specific T and B 
cell responses (Braciale et al., 2012; Kawai & Akira, 2008). IAV infection upregulates several 
inflammatory cytokines and chemokines, including CCL2 (MCP-1), CCL3 (MIP-1α), CCL5 
(RANTES), CXCL10 (IP-10) , IL-1β, IL-6, IL-8 and TNFα (Dawson et al., 2000; Herold et al., 
2008; Lin et al., 2008; Perrone et al., 2008). The adaptive immune responses are critical for virus 
clearance and host protection through a virus-specific response as well as the development of 
immunologic memory (Chiu & Openshaw, 2015).  IAV infections elicit virus-specific antibodies 
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(Mancini et al., 2011; Potter & Oxford, 1979). Particularly antibodies targeting for the two 
surface glycoproteins, HA and NA proteins, are important for their role in inducing the 
protective immunity (Gerhard, 2001). HA-specific antibodies are able to neutralize the virus 
infection by inhibiting virus attachment and entry into the cells. Antibodies binding to NA 
proteins also have protective potential by inhibiting the release and spread of progeny virus 
particles. These antibodies which are elicited through either past infection or vaccination mainly 
protect against the matching strains causing the infections. Therefore, the surface proteins of 
IAVs undergo the rapid evolutionary changes in response to the selective pressure of the host 
immune system and as a result, new IAV variants are generated to escape the host protective 
immunity (Smith et al., 2004). This is why the seasonal influenza vaccine needs to be updated 
annually to avoid the antigenic mismatch between epidemic strains and vaccine strains. However, 
some of the antibodies binding to the HA stem region, M2 or NP proteins which are highly 
conserved among different IAV subtypes can provide a broad immunity not only against the 
same IAV subtypes but also different IAV subtypes (Carragher et al., 2008; Ekiert et al., 2009; 
Epstein et al., 2005; Frace et al., 1999; Sui et al., 2009). During IAV infections, cytotoxic T 
lymphocytes (CTLs) contribute to the viral clearance and heterosubtypic immunity. The CTLs 
are activated in lymphoid tissues and are recruited into influenza virus-infected sites. 
Subsequently, they recognize and eliminate the cells infected with IAVs and as a result, inhibit 
spread of progeny viruses (McMichael et al., 1983). Upon IAV infection, the activated CTLs 
mostly target the conserved internal proteins of IAVs, such as PA, NP and M1 proteins (Boon et 
al., 2002; Gotch et al., 1987a; Gotch et al., 1987b; Jameson et al., 1998; Yewdell et al., 1985). 
Therefore, CTL-mediated immunity provides a cross-reactive protection during heterosubtypic 
IAV infections (Jameson et al., 1999; Kreijtz et al., 2008; Lee et al., 2008; Tu et al., 2010).  
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 Immunopathology 
The host immune responses are critical for the protection of the host from virus infections. 
However, an excessive immune response can be detrimental. Following viral infection, the initial 
innate immune response activates pro-inflammatory cytokines and chemokines which induce the 
recruitment of inflammatory cells at the viral infected site. In some cases, the hyperinduction of 
cytokines and chemokine also known as a cytokine storm, induces severe inflammation with 
excessive immune cell infiltration and causes serious pathological tissue damage (Tisoncik et al., 
2012). Furthermore, the severe inflammatory responses associated with cytokine storms can 
cause systemic cytokine storms to occur, which may subsequently lead to multi-organ 
dysfunction (Tisoncik et al., 2012). In most cases of IAV infection, innate and adaptive immune 
systems induce appropriate protective immunity for the host. However, several fatal cases, 
particularly 1918 H1N1, HPAI H5N1, 2009 pandemic H1N1 as well as the recent H7N9 human 
infections have displayed the influenza-induced cytokine storm (de Jong et al., 2006; Gao et al., 
2013b; Shen et al., 2014; Tiwari et al., 2014; Tumpey et al., 2005b; Yu et al., 2013). This 
excessive immune response damages lung tissues with serious immunopathological changes, 
reducing the respiratory capacity and ultimately leads to death. In addition to the virus strains, 
the differential expressions of IAV proteins, such as NS1, PB1-F2 and PA-X proteins which are 
correlated with modulation of host innate immune response can affect the induction of 
immunopathological changes in the lower respiratory tract (Hayashi et al., 2015; Jagger et al., 
2012; Jiao et al., 2008; McAuley et al., 2007). There is accumulating evidence that CTL-
meditated immunity is also responsible for immunopathology during IAV infections. Excessive 
infiltration of CTLs and overproduction of inflammatory cytokines, such as TNF-α and IFN-γ 
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from CTLs can cause severe lung immunopathology (DeBerge et al., 2014; Ramana et al., 2015; 
Small et al., 2001; Xu et al., 2004b).            
 1.10 IAV virulence factors 
To achieve interspecies transmission and infect other hosts, IAVs need to overcome the 
species barriers and interact with host-specific factors. Hence, IAVs change the genetic traits 
which are related with virulence and host range to increase viral virulence and to achieve the 
successful transmission and adaptation in new hosts.  
 HA 
Since the HA protein initiates IAV infection by attachment to cellular receptors and by 
inducing membrane fusion, the HA protein is an important determinant of the host range and 
tissue tropism of IAVs, which influences viral pathogenicity. It is known that different IAVs 
have different receptor specificities. Human IAVs have the preference to recognize α2,6-linked 
SA receptors which are abundantly expressed on epithelial cells along the human upper 
respiratory tract (URT), while avian IAVs preferentially bind to α2,3-linked SA receptors which 
are predominantly found in the human lower respiratory tract (LRT) and in the avian intestinal 
tract (Connor et al., 1994; Matrosovich et al., 1997; Rogers & Paulson, 1983; Shinya et al., 
2006). Thus, avian IAVs can more efficiently replicate deep in the lungs of humans (van Riel et 
al., 2006). However, to achieve transmission to humans, AIVs need to gain binding affinity to 
α2,6-linked SA receptors in the URT of humans. Specific amino acid substitutions, particularly 
in the receptor-binding domain (RBD) of the HA protein can change the receptor specificities 
from α2,3-linked SAs to α2,6-linked SAs. For H2 and H3 IAV subtypes, amino acid 
substitutions at position 226 and 228 from the H3 numbering system (Q226L and G228S) in the 
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RBD can alter the receptor preference from α2,3-linked SAs to α2,6-linked SAs (Matrosovich et 
al., 2000; Naeve et al., 1984; Rogers & Paulson, 1983). For 1918 H1N1 and 2009 pandemic 
H1N1 viruses, substitutions E190D and D225G from the H3 numbering system are critical in 
altering receptor preference from avian to human receptors (Chutinimitkul et al., 2010a; Gamblin 
et al., 2004; Glaser et al., 2005; Kilander et al., 2010; Tumpey et al., 2007). Several studies have 
reported amino acid substitutions which are associated with altering the receptor preference from 
α2,3-linked SAs to α2,6-linked SAs in the HA protein of H5N1 HPAIVs(Chutinimitkul et al., 
2010b; Watanabe et al., 2011; Yamada et al., 2006). The novel H7N9 virus which emerged in 
China in 2013 is able to bind to both avian and human receptors with the mammalian adaptation 
mutation Q226L (van Riel et al., 2013). These AIVs which acquired the human receptor 
preference can infect epithelial cells in both the URT and LRT and increase the severity of 
disease in humans. In addition to amino acid substitutions in the RBD, changes to the 
glycosylation site can influence the HA affinity for the two different receptors as well as the 
virulence of IAVs. For the 1918 H1N1 and 2009 pandemic H1N1 viruses, glycosylation patterns 
are important to determine antigenicity as well as the HA receptor affinity and additional 
glycosylation sites increase the viral virulence (Sun et al., 2013; Zhang et al., 2013b).  In H5N1 
HPAIVs, loss of glycosylation sites near the RBD of HA was shown to alter the binding 
preference to the receptors and increase the virulence (Chen et al., 2007; Wang et al., 2010).  
The HA protein is initially synthesized as the precursor protein HA0 and is cleaved into 
two subunits, HA1 and HA2 (Klenk et al., 1975; Lazarowitz & Choppin, 1975). HPAIVs 
containing a multibasic cleavage site in the HA protein have different protease sensitivities, in 
contrast to both LPAIVs and mammalian IAVs containing a monobasic cleavage site in the HA 
protein. Therefore, the amino acid sequences in the cleavage site of the HA protein determine 
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cleavage activity by specific proteases from different tissues, which is the main determinant of 
pathogenicity of AIVs. The HA proteins of  LPAIVs and mammalian IAVs are cleaved by 
trypsin-like proteases which are only expressed in the respiratory and intestinal tract of avian 
species and in the respiratory tract of humans (Kawaoka & Webster, 1988). Thus, LPAIV 
infections are restricted to these organs. However, the HA protein of HPAIVs are activated by 
the ubiquitous furin-like proteases which provide the proteolytic activation of HA proteins in 
multiple organs, and consequently cause systemic viral replication with severe disease (Stieneke-
Grober et al., 1992). HPAIVs emerge from LPAIVs, specifically H5 and H7 subtypes by 
acquisition of a polybasic cleavage motif. Recent studies showed that introduction of a 
multibasic cleavage site into non-H5 and -H7 subtypes including H2, H4, H6, H8 and H14 
subtypes can induce a highly pathogenic phenotype in chickens (Munster et al., 2010; Veits et al., 
2012). In mammals, the effect of a multibasic cleavage site on viral pathogenicity is more 
diverse than in avian species, depending on hosts and virus strains.  Deletion of a multibasic 
cleavage site from HPAI H5N1 virus only induced respiratory tract infection in mice (Hatta et al., 
2001). In ferrets, the multibasic cleavage site in HPAI H5N1 virus was shown to be critical for 
systemic spread of viruses (Schrauwen et al., 2012; Suguitan et al., 2012). On the other hand, 
insertion of a mutibasic cleavage site in the HA protein of human H3N2 IAV did not show 
increased virulence in ferrets (Schrauwen et al., 2011). In the non-human primates, cynomolgus 
macaques, infection with HPAI H5N1 viruses only induced respiratory tract disease 
(Rimmelzwaan et al., 2001).  
 NA 
Considering the functions of HA and NA proteins, the optimal balance between HA and 
NA activities is important for efficient viral transmission and replication (Wagner et al., 2002). 
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The NA proteins of AIVs preferentially cleave α2,3-linked SAs, while the NA proteins from 
mammalian influenza viruses can cleave both α2,3-linked SAs and α2,6-linked SAs, suggesting 
the host-specific adaptation of NA proteins (de Graaf & Fouchier, 2014). In AIVs, amino acid 
deletions in the stalk regions of the NA protein have been frequently occurred during 
transmission of AIVs from wild waterfowls to domestic poultry. Although it has yet to be 
determined why the shortened NA stalk domain is selected in poultry, it could be correlated with 
sustaining functional HA and NA balance since it supports virus transmission from waterfowl to 
poultry with enhanced virulence (Baigent & McCauley, 2001; Hoffmann et al., 2012; Munier et 
al., 2010; Sorrell & Perez, 2007; Sorrell et al., 2010). In mammals, the short stalk region of the 
NA protein in H5N1 virus contributed to virulence in mice whereas the shortened NA stalk 
domain limited transmission of 2009 pandemic H1N1 virus between ferrets (Blumenkrantz et al., 
2013; Matsuoka et al., 2009). In 2003, HPAI H7N7 emerged in poultry in the Netherlands and 
caused one fatal case out of 89 human cases of conjunctivitis. Four unique amino acid 
substitutions in the NA gene were found in the HPAI H7N7 virus isolated from the fatal case 
compared to the viruses obtained from other patients (Fouchier et al., 2004). It was revealed that 
these substitutions promote NA enzymatic activity, supporting the efficient virus replication (de 
Wit et al., 2010).  
 NS1 
The NS1 protein has multiple functions as an important virulence determinant during 
IAV infection. The key role of the NS1 protein is IFN antagonism which is achieved through 
several different mechanisms. The NS1 protein prevents the activation of RIG-I by interacting 
with tripartite motif-containing protein 25 (TRIM25) which inhibits RIG-I ubiquitination, and by 
binding to viral RNAs to escape the detection by PRRs (Gack et al., 2009; Min & Krug, 2006; 
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Rajsbaum et al., 2012). The NS1 protein also inhibits the function of the RNA-dependent protein 
kinase (PKR) by forming a complex with the PKR (Lu et al., 1995; Min et al., 2007). In addition, 
the NS1 protein prevents the nuclear migration of transcription factors, such as NF-κB and IFN-
regulatory factor 3 (IRF3) which induce type1 IFN expression (Talon et al., 2000; Wang et al., 
2000). The NS1 protein downregulates the expression of host genes, including ISGs and IFNs by 
preventing the processing as well as nuclear export of cellular mRNAs and by interacting with 
cellular factor CPSF30 (cleavage and polyadenylation specific factor 4, 30kDa subunit) (Alonso-
Caplen & Krug, 1991; Fortes et al., 1994; Nemeroff et al., 1998; Qiu & Krug, 1994).   
Specific residues in the NS1 protein are closely associated with virulence of IAVs. One 
amino acid substitution at position 92 (D92E) of the NS1 protein is responsible for enhanced 
pathogenicity of HPAI H5N1 virus in mice and increased virulence of recombinant H1N1 IAVs 
which carried the NS gene of HPAI H5N1 in pigs by escaping the IFN antiviral response (Seo et 
al., 2002). The substitution at position 42 (P42S) of the NS1 protein in HPAI H5N1 virus 
increased virulence in mice and reduced type I IFN production in vitro (Jiao et al., 2008). In 
addition, L103F and I106M substitutions in the NS1 protein promoted NS1 binding to the 
CPSF30, which supports viral replication by suppressing the expression of type I IFNs (Twu et 
al., 2007). The C-terminus of the NS1 protein in both 1918 H1N1 and H5N1 HPAI viruses 
contains a PDZ ligand domain (X-S/T-X-V), which increased the virus virulence when this 
domain was introduced into a mouse adapted IAV strain (Jackson et al., 2008). Although the 
PDZ ligand domain is linked to viral virulence, the role of the PDZ ligand motif in IAV 
pathogenesis remains unclear. The 2009 pandemic H1N1virus lacks the CPSF30 binding ability 
and loses the PDZ ligand domain due to the expression of a truncated NS1 protein (Hale et al., 
2010b; Neumann et al., 2009). Interestingly, even if these functions are restored, they did not 
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show obvious effects on virus virulence and transmission in different animal models (Hale et al., 
2010a; Hale et al., 2010b).      
 Polymerase complex 
The polymerase complex of IAVs has been shown to be an important contributor to viral 
virulence. Particularly, the PB2 protein has been recognized to be a key determinant for virus 
adaptation to mammalian hosts and virulence. The E627K substitution in the PB2 protein is a 
remarkable genetic signature for the mammalian adaptation of AIVs. This mutation is present in 
previous pandemic viruses, including the 1918 H1N1, 1957 H2N2 and 1968 H3N2 viruses 
(Taubenberger & Morens, 2006; Taubenberger et al., 2005). This 627K adaptation was found in 
over 30% of human HPAI H5N1 isolates since 1997 and in most of the recent human H7N9 
isolates (Liu et al., 2013; Long et al., 2013). Since the polymerase activity of AIVs with the PB2 
627K residue was more active than with the PB2 627E residue at a lower temperature (33ºC), it 
was suggested that 627K in the PB2 protein could overcome the cold sensitivity of AIVs and 
support efficient viral replication at 33ºC in the human URT. Viruses with the PB2 627E can 
replicate efficiently at a higher temperature (41ºC) which is nearly same temperature of avian 
intestinal tract (Hatta et al., 2007; Massin et al., 2001). In the absence of the E627K mutation, 
the substitution D701N in the PB2 protein can compensate for the mammalian adaptation 
function of 627K in both human HPAI H5N1 and HPAI H7N7 viruses (de Wit et al., 2010; Li et 
al., 2005; Steel et al., 2009).  The D701N substitution increases binding of the PB2 protein to 
importin-α which is a component of the nuclear import machinery for vRNPs and enables 
efficient viral replication in mammalian cells (Gabriel et al., 2008; Resa-Infante et al., 2008). 
The 2009 pandemic H1N1 virus possesses the typical avian virus residues in the PB2 protein, 
such as 627E and/or 701D while the introduction of substitutions E627K or D701N does not 
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increase the viral virulence in mice (Herfst et al., 2010). Instead, the substitutions G590S and 
Q591R in the PB2 protein of 2009 pandemic H1N1 virus compensate for the absence of 627K 
and support the virus replication in mammalian cells (Mehle & Doudna, 2009).  
In the PB1 protein, the substitution N375S is the genetic signature related with host 
adaptation from avian species to mammalians. The previous 1918, 1957 and 1968 human 
pandemic viruses contain this N375S substitution in the PB1 protein, while some H3N2 human 
strains have the 375N (Naffakh et al., 2008; Taubenberger et al., 2005). This indicates that the 
N375S substitution is not a strict host-range determinant.    
Several residues in the PA protein have been reported with the ability to increase the 
polymerase activity but they have no or only minimal influence on viral virulence in mice 
(Bussey et al., 2011; Gabriel et al., 2005).   
The NP protein determines the sensitivity of IAVs to host myxovirus resistance A (MxA) 
protein which is induced by IFNs as an important antiviral factor. The HPAI H5N1 virus with a 
reverse engineered NP protein from human H1N1 virus acquired the MxA resistance in 
mammalian cells (Dittmann et al., 2008). Adaptive mutations in the NP protein of 1918 H1N1 
and 2009 pandemic H1N1 viruses were identified to restrict the MxA sensitivity in human cells 
and these mutations in the NP protein increased viral virulence of HPAI H5N1 virus in mice 
(Manz et al., 2013). The N319K substitution in the NP protein has been reported to increase AIV 
replication in mammalian cells through promoting the interaction with imiportin-α (Gabriel et al., 
2005; Gabriel et al., 2008; Gabriel et al., 2011).  
 PB1-F2 
The PB1-F2 protein is an important virulence factor with diverse functions. The PB1-F2 
protein has pro-apoptotic activity in immune cells. It is localized to the mitochondria and 
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interacts with components of the permeability transition pore complex (PTPC), such as the 
voltage-dependent anion channel 1 (VDAC1) and the adenine nucleotide translocator 3 (ANT3), 
which results in alteration of the mitochondria permeability. This change in mitochondria 
induces the formation of membrane pores followed by cytochrome C release and subsequently 
leads to apoptosis (Chanturiya et al., 2004; Chen et al., 2001; Lowy, 2003; Zamarin et al., 2005). 
The PB1-F2 protein regulates polymerase activity by interacting with PB1 protein in the nucleus 
(Mazur et al., 2008; McAuley et al., 2010). In addition, the PB1-F2 protein enhances viral 
pathogenicity by modulating the innate immune response which promotes lung inflammation and 
also by increasing the frequency as well as severity of secondary bacterial infection (Alymova et 
al., 2014; Le Goffic et al., 2007; McAuley et al., 2007; Zamarin et al., 2006). Several amino acid 
residues in the PB1-F2 protein have been identified as inflammatory residues (L62, R75, R79 
and L82) or cytotoxic residues (I68, L69 and V70), which are related with the enhancement of 
viral pathogenicity (Alymova et al., 2011; Alymova et al., 2014). Moreover, the single 
substitution N66S in PB1-F2 has been shown to increase the viral virulence of 1918 H1N1 and 
HPAI H5N1 viruses in mice due to the delayed IFN response (Conenello et al., 2007; Schmolke 
et al., 2011). The PB1-F2 protein with 66S can interact with the mitochondrial antiviral signaling 
protein (MAVS) more efficiently than the PB1-F2 protein with 66N and this increased 
interaction suppresses the early induction of type I IFNs as well as ISGs (Conenello et al., 2011; 
Varga et al., 2012). Most avian IAVs express the full-length PB1-F2 protein with over 78 amino 
acid residues, whereas swine and human IAVs, including 2009 pandemic H1N1 virus commonly 
have truncated PB1-F2 proteins (Pasricha et al., 2013; Zell et al., 2007). This suggests that there 
could be selective benefits for truncated PB1-F2 protein in IAVs to adapt to the mammalian 
hosts. However, several recent studies found that these PB1-F2 functions act in a virus strain and 
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host dependent manner. In a previous study, the PB1-F2 expression in H5N1 HPAIV had a 
minor effect on pathogenicity in a mouse model, while PB1-F2 protein contributed to the 
virulence in ducks (Schmolke et al., 2011). In contrast, one recent study demonstrated that the 
PB1-F2 protein attenuated pathogenicity of H5N1 HPAIV in chickens (Leymarie et al., 2014). In 
a swine model, restored PB1-F2 protein had minimal effect on viral pathogenicity of the 2009 
pH1N1 virus (Pena et al., 2012b). In addition, the PB1-F2 protein of TR H3N2 SIV modulated 
the viral virulence in a strain-dependent fashion in pigs and also altered viral pathogenicity and 
transmission in turkeys (Deventhiran et al., 2015; Pena et al., 2012a).  
 PA-X 
It has been demonstrated that the PA-X protein is involved in the modulation of host 
response as well as viral virulence. The functional role of the PA-X protein is clearly related with 
the host-shutoff activity. The PA-X protein contains the N-terminal endonuclease domain which 
mediates the degradation of the cellular mRNAs (Jagger et al., 2012). The PA-X protein targets 
polymerase II-transcribed RNAs in nucleus and selectively degrades the host mRNAs, while 
IAV mRNAs resist the mRNA degradation mediated by the PA-X during the IAV infections 
(Khaperskyy et al., 2016). However, it is still unclear how the PA-X protein discriminates 
between the host mRNAs and IAV mRNAs, and targets the host mRNAs to degrade them. The 
host-shutoff activity of the PA-X protein mainly targets the expression of apoptosis, 
inflammatory and immune response-related genes (Jagger et al., 2012). Therefore, the PA-X 
deficient virus showed increased apoptosis and upregulated inflammatory as well as immune 
responses. However, the effect of the PA-X protein on viral pathogenicity is depending on virus 
strains and hosts. The PA-X expression in 1918 H1N1 and HPAI H5N1 viruses attenuated the 
viral virulence with reduced pathological lung damages by suppressed immune response in mice 
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or chickens (Hu et al., 2015; Jagger et al., 2012). On the other hand, 2009 pandemic H1N1 virus 
with the PA-X expression showed the increased viral virulence with enhanced viral replication in 
mouse lungs by suppressed immune response (Hayashi et al., 2015). Although the PA-X protein 
contains the identical N-terminal endonuclease domain with the PA protein, the PA-X protein 
showed a stronger host shutoff activity compared to the PA protein (Desmet et al., 2013). This 
indicates that the PA-X unique C-terminal domain plays an important role in suppression of the 
host gene expression and in agreement with this, recent two studies reported that the first 15 
amino acids in the C-terminal region of PA-X protein are critical for maximum shutoff activity 
of PA-X protein (Hayashi et al., 2016; Oishi et al., 2015).    
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Chapter 2 - Effects of PB1-F2 on the pathogenicity of H1N1 swine 
influenza virus in mice and pigs 
Abstract:  
Although several studies have exploited effects of PB2-F2 in swine influenza viruses, its 
contribution to the pathogenicity of swine influenza viruses remains unclear. Herein, we 
investigated effects of PB1-F2 on the pathogenicity of influenza virus using a virulent H1N1 
A/swine/Kansas/77778/2007 (KS07) virus, which expresses a full-length PB1-F2, in mice and 
pigs. Using reverse genetics, we generated the wild type KS07 (KS07_WT), a PB1-F2 knockout 
mutant (KS07_K/O) and its N66S variant (KS07_N66S). KS07_K/O showed similar 
pathogenicity in mice as the KS07_WT, whereas KS07_N66S displayed enhanced virulence 
when compared to the other two viruses. KS07_WT exhibited more efficient replication in lungs 
and nasal shedding in infected pigs than the other two viruses. Pigs infected with the KS07_WT 
had higher pulmonary levels of GM-CSF, IFN-γ, IL-6 and IL-8 at 3 and 5 days post-infection, as 
well as lower levels of IL-2, IL-4 and IL-12 at 1 day post infection compared to those infected 
with the KS07_K/O. These results indicate that PB1-F2 modulates KS07 H1N1 virus replication, 
pathogenicity and innate immune responses in pigs, and the single substitution at position 66 
(N/S) in the PB1-F2 plays a critical role in virulence in mice. Taken together, our results provide 
new insights into the effects of PB1-F2 on the virulence of influenza virus in swine, and support 
PB1-F2 as a virulence factor of influenza A virus in a strain- and host-dependent manner. 
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 2.1 Introduction 
Influenza A virus (IAV) is a single-stranded negative sense RNA virus of the 
Orthomyxoviridae family that infects a wide variety of host species, from wild and domestic 
birds to several mammalian species including humans. It causes annual epidemics and occasional 
pandemics in humans, which leads to significant public health and economic burdens worldwide. 
Swine influenza is caused by IAV and is an important acute respiratory disease to the swine 
industry and has also become a considerable zoonotic agent that threatens public health (Dowdle 
& Hattwick, 1977; Myers et al., 2007). This fact is exemplified by the 2009 pandemic H1N1 
influenza virus that is considered to be a swine-origin virus (Peiris et al., 2009). 
The first swine influenza virus (SIV) isolated from pigs was the H1N1 subtype in 1930 
(Shope, 1931), also known as the classical H1N1 virus (cH1N1), which circulated predominantly 
in North American swine herds until 1998. Then, a novel triple-reassortant (TR) H3N2 SIV 
emerged in 1998 and successfully became established and widespread in North American pig 
populations  (Webby et al., 2000; Zhou et al., 2000). The TR H3N2 virus contains the 
hemagluttinin (HA), neuraminidase (NA) and PB1 genes from human IAVs; the PB2 and PA 
genes from avian IAVs; and the M, NP and NS genes from the cH1N1 virus (Webby et al., 2000; 
Zhou et al., 2000). Subsequently, TR H3N2 viruses reassorted with cH1N1 SIVs and human 
seasonal H1N1 viruses, resulting in novel reassortants such as H1N2, reassortant H1N1 (rH1N1) 
and H3N2 SIVs which have become endemic in North American swine herds (Karasin et al., 
2000; Lekcharoensuk et al., 2006; Vincent et al., 2008; Webby et al., 2004). These reassortant 
viruses have a similar composition of six internal genes of human origin (PB1), avian origin 
(PB2 and PA) and classical swine origin (M, NS and NP), which has been called the triple-
reassortant internal gene cassette (TRIG) (Ma et al., 2009; Vincent et al., 2008). The TRIG 
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cassette is readily able to accept different HA and NA combinations (Vincent et al., 2008). With 
the introduction of 2009 pandemic H1N1 virus into pigs, the TRIG M gene was replaced by the 
Eurasian swine M gene (Nelson et al., 2015; Nelson et al., 2012).    
IAV contains eight viral RNA segments which encode 10 to 17 viral proteins depending 
on the strain. The PB1-F2 protein discovered in 2001 is a small non-structural protein which is 
encoded by alternative translation from the PB1 genome (Chen et al., 2001). Although it can 
have various lengths from 8 to 101 amino acids, it generally consists of 90 amino acids. The 
PB1-F2 protein is known to be an important virulence factor with diverse functions. It is 
localized into the mitochondria and induces apoptosis by interacting with the mitochondrial-
dependent apoptotic pathway (Chen et al., 2001; Lowy, 2003). In most avian IAVs, PB1-F2 
proteins are expressed in their full-length form (over 78 amino acid residues), while human and 
swine influenza viruses commonly express truncated PB1-F2 proteins. This suggests that 
truncated PB1-F2 proteins could be beneficial for adaptation of the virus to the mammalian host 
(Pasricha et al., 2013; Zell et al., 2007). Overall, the PB1-F2 protein is associated with the 
survival advantage of IAV in different hosts and modulates virus pathogenicity in a strain- and 
host-dependent manner. A previous study has shown that restoring the PB1-F2 open reading 
frame (ORF) in the context of the 2009 pandemic H1N1 virus has minimal effects in swine (Pena 
et al., 2012b). Although numerous studies that investigate the effects of PB1-F2 on virus 
pathogenicity and transmissibility of different IAVs in different animal models have been 
published (Deventhiran et al., 2015; Leymarie et al., 2014; Pena et al., 2012a; Schmolke et al., 
2011; Zamarin et al., 2006), the contribution of the PB1-F2 protein to the viral pathogenicity of 
IAVs in natural hosts such as birds and pigs remains unclear.  
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In this study, we used a virulent TR H1N1 SIV, A/swine/Kansas/77778/2007 (KS07) 
which has a human-origin PB1gene and expresses a full-length PB1-F2 protein, to investigate the 
effects of PB1-F2 on viral pathogenicity in a mouse model and in a natural host, pigs.  
 2.2 Materials and Methods 
 Cells and virus strain 
Human embryonic kidney (293T) cells were maintained in Opti- modified Minimal 
Essential Medium (MEM) containing 10% fetal bovine serum (FBS) (Hyclone) and 1% 
antibiotic-antimycotic (Gibco). Madin-Darby canine kidney (MDCK) cells were cultured in 
Minimal Essential Medium (MEM) with 5% FBS, 1% antibiotic-antimycotic, 2mM L-glutamine 
(Gibco) and 1x MEM vitamin solution (Gibco). Porcine kidney (PK-15) cells were grown in 
Dulbecco's modified Eagle medium (DMEM) supplemented with 5% FBS, 2mM L-glutamine, 
1x MEM vitamin solution and 1% antibiotic-antimycotic. MEM infecting media containing 0.3% 
bovine serum albumins (BSA) (Sigma-Aldrich), 1% antibiotic-antimycotic and 1μg/ml TPCK-
treated trypsin (Sigma-Aldrich) were used for virus infection of cells. The TR H1N1 SIV 
A/swine/Kansas/77778/2007 (KS07) (GenBank accession number: GQ484355-GQ484362) was 
isolated from diseased pigs as previously described (Ma et al., 2010) and was used for this study. 
Plasmid constructions and rescue of recombinant viruses 
Eight-gene segments of KS07 were amplified and cloned into a pHW2000 vector as 
described previously (Hoffmann et al., 2000; Hoffmann et al., 2001). To generate the KS07 
PB1-F2 knockout gene, the PB1-F2 expression initiation start codon and three possible 
downstream start codons were mutated from ATG to ACG (T120C, T234C, T255C and T270C) 
while one stop codon was mutated from TAA to TTA (A390T) using a GeneArt® site-directed 
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mutagenesis kit (Invitrogen) according to the manufacturer’s instructions. A single amino acid 
substitution at position 66 of the PB1-F2 (N66S) was introduced, which has been shown to be 
associated with increased virulence in mice (Conenello et al., 2007). None of the mutations 
altered the PB1 open reading frame (ORF) as silent mutations. The sequences of the constructed 
plasmids and introduced mutations were confirmed by sequencing (Sanger DNA Sequencing 
service provided by GENEWIZ). 
Wild type (KS07_WT), PB1-F2 knocked out (KS07_K/O) and N66S single mutant 
(KS07_N66S) viruses were generated by reverse genetics as described previously (Hoffmann et 
al., 2000). Briefly, co-cultured MDCK and 293T cells were transfected with eight constructed 
pHW2000 plasmids encoding viral genomic RNA segments using Lipofectamine 2000 
(Invitrogen). After 48hr of transfection, supernatants were collected and passaged three times on 
MDCK cells. The rescued viruses were confirmed by sequencing (Sanger DNA Sequencing 
service provided by GENEWIZ).    
 Growth kinetics 
To evaluate the replication kinetics of recombinant viruses, MDCK and PK-15 cells were 
grown in 12-well plates and infected with each virus at a multiplicity of infection (MOI) of 0.001 
in triplicate. Cell culture supernatants were collected at 12, 24, 36 and 48 hours post-infection 
(hpi). Virus titers were determined by calculating the 50% tissue culture infective dose 
(TCID50)/ml in MDCK cells using the Reed and Muench method. The plaque assay was 
performed to compare the size of plaques formed by each recombinant virus on MDCK cells.   
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 Pathogenicity study in mice 
Six-week-old female BALB/c mice were used for the pathogenicity study. A total of 56 
mice were randomly divided into four groups (14 mice/group). Mice from each group were 
inoculated intranasally (IN) with 1.5 x 10
6 
TCID50 of each virus in a volume of 50 μl under slight 
anesthesia with isoflurane. For the control group, mice were mock-infected with 50 μl of virus-
free MEM. Mice were monitored daily for clinical signs and weighed daily until 14 days post 
infection (dpi). If mice lost more than 25% of their original body weight, they were humanly 
euthanized. Three mice from each group were euthanized at 3 and 7 dpi and lungs were collected 
from each mouse to assess virus replication and to perform histopathological analysis. For virus 
titration, 10% lung homogenates were made using fresh MEM with 1 % antibiotic-antimycotic, 
and virus titers in the lung homogenates were determined on MDCK cells. 
 Pathogenicity study in pigs 
Thirty-five 3 to 4-week-old pigs, which were confirmed to be seronegative for porcine 
reproductive and respiratory syndrome virus and SIVs, were used in this study. Each infection 
group contained nine pigs while the control group contained eight pigs and each group was 
housed in separate isolation rooms. Pigs were intratracheally infected with 1 x 10
3
 TCID50 of 
each recombinant virus or with virus-free MEM as controls. Body temperature and clinical 
symptoms were monitored daily. At 0, 1, 3 and 5 dpi, nasal swabs were collected from each pig 
and processed for virus titration on MDCK cells. Three pigs from each group were necropsied at 
1 and 3 dpi; three pigs from each infection group and two pigs of the control group were 
necropsied at 5 dpi. At necropsy, lungs were removed in toto, and the percentage of gross lesions 
on each lobe (each lung lobe is considered as 100%) was assessed by a single experienced 
veterinarian. The mean of gross lung lesions of seven lung lobes were calculated and presented 
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for the average lung lesions of each pig. Bronchoalveolar lavage fluid (BALF) samples were 
collected by flushing each lung with 50ml fresh MEM and viral titers were determined on 
MDCK cells by calculating the TCID50/ml. 
 Histopathology and immunohistochemistry 
Tissue samples (right lungs from mice and nasal turbinates, trachea, as well as right 
cardiac lung lobes from pigs) were fixed in 10% neutral buffered formalin and processed by the 
histopathology and immunohistochemistry laboratory of the Kansas State Veterinary Diagnostic 
Laboratory (KSVDL). A board-certified veterinary pathologist evaluated histopathological 
lesions of hematoxylin and eosin (H&E) stained tissues. Immunohistochemistry (IHC) staining 
for mouse lungs was conducted to detect influenza virus antigen in tissues using an anti-
influenza A NP monoclonal antibody (mAb). The primary antibody was detected with the Leica 
Bond Polymer Refine Detection Kit on the Leica Bond-Max. For the lung microscopic lesions in 
mice, lungs were graded on the following seven criteria: Subjective percentage of lung involved 
in the histological section examined (4 point scale of 1-4); airway epithelial necrosis, 
neutrophilic airway inflammation, peribronchiolar lymphocyte cuffing, interstitial pneumonia, 
airway epithelial hyperplasia (all on a 3 point scale of 1-3); and lastly the presence and absence 
of hyaline membranes (2 point scale, 0=absent and 1=present). In pigs, microscopic lesions were 
graded on a 0-3 or 0-4 scale for percentage of airways with epithelial necrosis or inflammation 
(0-4), peribronchiolar lymphocyte cuffing (0-3), interstitial pneumonia (0-4), airway epithelial 
hyperplasia (0-4), respiratory epithelial degeneration and necrosis in nasal turbinates and trachea 
(0-4), and degree of inflammation in trachea and nasal turbinates (0-3) similar to that described 
previously.   
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 Cytokine and chemokine levels in BALF 
Expressions of 12 porcine cytokines/chemokines (GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, 
IL-4, IL-6, IL-8, IL-10, IL-12, IL-18 and TNF-α) in BALF were quantified by MILLIPLEX 
MAP Porcine Cytokine/Chemokine Magnetic Bead Panel using the Luminex technology 
following the manufacturer’s instructions (Millipore). The data was read and analyzed by a Bio-
Plex 200 Suspension Array Luminex System (Bio-Rad). 
 Statistical analysis 
For statistical analysis among groups, analysis of variance (ANOVA) test was used in 
GraphPad Prism version 5.0 (GraphPad Software). For comparisons of survival curves, a log-
rank test was performed. A p value of 0.05 or less was considered statistically significant. 
 2.3 Results 
 Generation and characterization of wild type KS07 and its mutated viruses in vitro 
KS07_WT and its mutated viruses including both KS07_K/O and KS07_N66S were 
generated by reverse genetics and confirmed by sequencing. Since the N66S substitution in PB1-
F2 protein is associated with enhanced virulence in mice as shown previously (Conenello et al., 
2007), we generated the mutant KS07_N66S virus to determine whether the effect of this 
mutation can be applied to the swine-adapted KS07 virus either in mice or in pigs. The rescued 
three viruses replicated efficiently in MDCK cells and amplified viruses were used for further 
characterization.  The plaque assay showed that KS07_WT as well as both mutated KS07_K/O 
and KS07_N66S viruses formed similar small pinpoint plaques in MDCK cells (Figure 2-1A). 
KS07_WT and its two mutated viruses grew efficiently in both MDCK and PK-15 cells, and 
their titers reached approximately 10
8
 TCID50/ml; however, no significant difference was 
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observed between the three viruses in their growth kinetics (Figure 2-1B). In MDCK cells, all 
three viruses reached their peak virus titer at 24 hpi while in PK-15 cells, they showed their peak 
virus titer at 48hpi (Figure 2-1B). These results indicate that both PB1-F2 knock-out and single 
substitution N66S in the PB1-F2 do not affect virus replication and phenotype in tested cells. 
 PB1-F2 in KS07 does not affect virus replication and pathogenicity in mice while 
KS07_N66S enhances virulence in mice 
As the KS07 H1N1 SIV is not a mouse adapted virus, we infected BALB/c mice with a 
high dose (1.5 x 10
6 
TCID50/mouse) of each virus to evaluate the effect of PB1-F2 on viral 
pathogenicity. All infected mice showed clinical symptoms such as depression, decreased 
activities, ruffled fur and obvious weight loss starting at 2 dpi when compared to the control 
mice. In contrast, KS07_N66S induced more severe body weight loss than both KS07_WT and 
KS07_K/O viruses, resulting in 100% mortality by 8 dpi (Figure 2-2). Both KS07_WT and 
KS07_K/O caused 75% mortality in infected mice (Figure 2-2B); however, surviving mice 
infected with KS07_K/O started to recover two days earlier (6 dpi) compared to those infected 
with KS07_WT (8 dpi) (Figure 2-2A). Interestingly, KS07_K/O replicated to a significantly 
higher virus titer in mouse lungs than the KS07_N66S at 3 dpi, whereas virus titers in the mouse 
lungs were similar among three infection groups at 7 dpi ( Figure 2-3A). Histopathological 
analysis showed that all three infection groups exhibited more severe lung damages at 7 dpi 
when compared to those at 3 dpi despite no significant differences of histopathological scores 
observed between different groups at each time point ( Figure 2-3B). In mice, most had varying 
degrees of neutrophilic airway inflammation, airway epithelial degeneration and necrosis, 
peribronchiolar lymphocytic cuffing, interstitial pneumonia, and epithelial hyperplasia (Figure 
2-4). A small number of mice (n=6) also had hyaline membranes lining alveoli (Figure 2-4). NP 
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antigen deposition of IAV was detected in lung tissues from each mouse in all three infection 
groups at 3 and 7 dpi by IHC staining (Figure 2-4). 
 PB1-F2 has moderate effects on viral pathogenicity in pigs 
A previous study showed that minimal effects were observed in pigs inoculated with a 
high dose (10
5 
TCID50/pig) of 2009 pandemic H1N1 virus expressing either full-length or 
nonfunctional PB1-F2 protein (Pena et al., 2012b) and our former studies also demonstrated that 
the 2009 pandemic H1N1 is virulent and causes disease in pigs (Ma et al., 2011). As the KS07 
virus is virulent in pigs, three to four-week-old pigs were infected with a low dose (10
3 
TCID50/pig) of each virus to investigate the effect of PB1-F2 and single substitution N66S in 
PB1-F2 on viral pathogenicity. None of the infected pigs presented obvious respiratory 
symptoms such as nasal secretion, coughing or sneezing. Several pigs in each infection group 
(5/9 pigs in KS_WT group, 6/9 pigs in KS07_K/O or in KS07_N66S group) had mild fever 
starting at 1 dpi and lasted 1-2 days; only one pig in the KS07_N66S group had a fever lasting 
for five days. During necropsy, no gross lung lesions were observed in any of the three pigs 
infected with either the KS07_WT or KS07_K/O virus at 1 dpi, whereas two out of three 
KS07_N66S infected pigs exhibited minimal gross lung lesions (averaged less than 1 %) (Figure 
2-5A). Interestingly, KS07_K/O induced more macroscopic lesions in infected pigs that spread 
to 5-6 lung lobes when compared to the other two viruses at 3 dpi. At 5 dpi, lung lesions were 
present in each lung lobe of each infected pig of three groups, but lower lesions were observed in 
the pigs infected with the KS07_N66S virus (Figure 2-5A).  
All three recombinant viruses replicated in the lungs of infected pigs. Virus was detected 
from bronchoalvelolar lavage fluid (BALF) samples collected at 1, 3 and 5 dpi from all infected 
pigs with the KS07_WT (Figure 2-5B). In contrast, virus was detected in bronchoalveolar lavage 
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fluid (BALF) from only two of three pigs at 1 and 3 dpi in the KS07_K/O infected group, and in 
all three pigs at 5 dpi. On the other hand, virus was detected in BALF from two of three pigs in 
the KS07_N66S infected group at 1 and 5 dpi, and in all three infected pigs at 3 dpi (Figure 
2-5B). Although virus titers were variable between different groups, there were no significant 
differences of virus titers between three infected groups.  No virus was detected in nasal swab 
samples collected from infected pigs of each group at 1 dpi (Figure 2-5C). Virus nasal shedding 
was detected from five of six pigs infected with the KS07_WT virus and from four out of six 
pigs infected with either the KS07_K/O or the KS07_N66S virus at 3 dpi. Virus was found in 
nasal swabs collected from all three infected pigs of each group at 5 dpi (Figure 2-5C). Virus 
titer of nasal shedding of the KS07_WT group was higher than those of the other two infection 
groups despite no significant differences in virus titers observed among infected groups.   
Nasal turbinate, trachea and lungs collected from pigs necropsied at 1, 3 and 5 dpi were 
examined for histopathological analysis (Table 2-1and Figure 2-6). Microscopic lesions were not 
found in these three tissues of control pigs at the three time points. All influenza infected pigs 
showed pulmonary lesions characterized by varying degrees of interstitial pneumonia, 
bronchiolar epithelial necrosis and bronchiolitis with peribronchiolar lymphocytic cuffing, 
airway epithelial hyperplasia and had different degrees of tracheal (Figure 2-6) and nasal cavity 
inflammation and necrosis. Microscopic lesions were found in the lung tissues of all three pigs 
infected with the KS07_WT virus at 1 dpi; however, none of the three pigs infected with the 
KS07_N66S has lung lesions and two of three pigs infected with the KS07_K/O displayed 
lesions in lung tissues (Table 2-1). Microscopic lesions were observed in trachea tissues of all 
three pigs infected with the KS07_WT virus at 1 dpi, but only one of three pigs infected with 
either the KS07_N66S or the KS07_K/O had lesions in the trachea (Table 2-1). Lung lesions 
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were found in three or two pigs infected with the KS07_K/O at 3 and 5 dpi respectively; one or 
none of pigs in the other two infection groups showed microscopic lung lesions at 3 and 5 dpi. 
One or two pigs from each infected group showed lesions in nasal turbinate tissues at 1 and 3 
dpi, while no pigs had lesions in this tissue at 5 dpi (Table 2-1). In contrast to both KS07_WT 
and KS07_K/O viruses, the KS07_N66S virus induced less histopathological lung and trachea 
damages in pigs (Table 2-1). 
 PB1-F2 modulates host immune responses in pigs 
To investigate the effects of PB1-F2 expression in KS07 on the host immune response, 
we next assessed the pulmonary levels of cytokines and chemokines in BALF collected from 
each pig at 1, 3 and 5 dpi (Figure 2-7). All measured chemokine and cytokine levels in BALF 
from KS07_N66S infected pigs were similar to those of control pigs except for IL-1β and IL-6 at 
5 dpi. All tested cytokine/chemokines except TNF-α in KS07_WT infected pigs and six 
cytokine/chemokines including IL-1β, IL-2, IL-4, IL-6, IL-10 and IL-12 in KS07_K/O infected 
pigs were significantly higher compared to those detected in control pigs at 3 or 5 dpi. The 
KS07_WT infected group showed lower levels of all tested cytokine/chemokines including 
significantly lower expression of IL-2, IL-4 and IL-12 than the KS07_K/O infected group at 1 
dpi. In contrast, KS07_WT infected pigs had higher levels of all tested cytokine/chemokines 
including significantly higher levels of GM-CSF, IFN-γ, IL-6 and IL-8 than those in the 
KS07_K/O infected pigs at 3 or 5 dpi. Collectively, N66S substitution in PB1-F2 protein of the 
KS07 virus has minor effect on innate immune responses in pigs. On the other hand, PB1-F2 
protein expression suppresses innate immune responses at early time points while PB1-F2 
protein upregulates cytokine/chemokine expression at later time points in pigs. This data 
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indicates that PB1-F2 modulates immune responses in pigs during viral infection with the KS07 
virus. 
 2.4 Discussion 
The PB1-F2 protein is an accessary protein encoded from the +1 ORF in PB1 gene 
through leaky ribosomal scanning. It has been shown to play important roles in IAV replication 
that includes cell type- and virus strain-specific proapoptotic functions (Chen et al., 2010; Chen 
et al., 2001; Lowy, 2003; Zamarin et al., 2005), and regulation of polymerase activity by co-
localization as well as interacting with PB1 (Mazur et al., 2008; McAuley et al., 2010). 
Furthermore, the PB1-F2 protein modulates the innate immune response and pro-inflammatory 
reactions which exacerbate or attenuate IAV pathogenicity (Le Goffic et al., 2010; Leymarie et 
al., 2014). It also facilitates secondary bacterial infection in a mouse model (Alymova et al., 
2014; McAuley et al., 2007). It has been shown that the PB1-F2 protein has effects on viral 
pathogenicity in a strain- and host-dependent manner. In H5N1 highly pathogenic avian IAVs 
(HPAIVs), the PB1-F2 protein has shown different contributions to viral pathogenicity in 
different hosts such as mice, ducks and chickens (Leymarie et al., 2014; Schmolke et al., 2011). 
In addition, restoring PB1-F2 in the 2009 pandemic H1N1 influenza virus has minimal effects in 
pigs (Pena et al., 2012b). In TR H3N2 SIVs, PB1-F2 expression has strain-dependent effects in 
swine and altered viral pathogenicity and transmission in turkeys (Deventhiran et al., 2015; Pena 
et al., 2012a).  
Although previous studies have shown effects of PB1-F2 in low virulent SIVs in pigs 
(Deventhiran et al., 2015; Pena et al., 2012a) and a former study has suggested a very low level 
of PB1-F2 expression in SIV infected cells (Buehler et al., 2013), the effect of PB1-F2 protein in 
a highly virulent SIV on viral pathogenicity in different animal models remains unclear. 
60 
Therefore, in this study we selected a highly virulent H1N1 TR SIV that caused approximately 
10% mortality in finishing pigs (Ma et al., 2010) and expresses a full-length PB1-F2 protein. Our 
results showed that the expression of PB1-F2 and the presence of the N66S mutation in the KS07 
virus had no effect on virus replication in both MDCK and PK-15 cells as well as on the 
formation of plaques in MDCK cells (Figure 2-1). These results are in agreement with a previous 
study that showed PB1-F2 expression in TR H3N2 SIVs did not impact virus replication in A549 
and 3D4/31 cells (Deventhiran et al., 2015). In contrast, Pena et al. described that PB1-F2 
expression in two different TR H3N2 SIV backgrounds had a different impact on virus 
replication kinetics in porcine alveolar macrophages and porcine respiratory explants (Pena et 
al., 2012a). These findings support the hypothesis that the effects of PB1-F2 are cell type- and 
virus strain-specific in vitro.     
In mice, PB1-F2 expression in 1918 H1N1 virus enhanced the viral pathogenicity and the 
N66S mutation in PB1-F2 protein of this virus contributed to increase virulence (Conenello et 
al., 2007; McAuley et al., 2007). Another previous study found that expression of full-length or 
truncated PB1-F2 protein or its N66S substitution in 2009 pandemic H1N1 virus does not have a 
significant impact on virulence in both DBA/2 and BALB/c mice (Hai et al., 2010). In addition, 
the N66S substitution in the PB1-F2 protein of H5N1 HPAIV showed increased replication and 
virulence, while deletion of the PB1-F2 protein had no effect on viral pathogenicity in mice 
(Schmolke et al., 2011). In our mouse study, the PB1-F2 knockout mutant did not alter viral 
virulence when compare to the KS07_WT virus; however, the single substitution N66S in PB1-
F2 resulted in enhanced virulence in mice, evidenced by inducing severe disease and 100% 
mortality in infected mice when compared to either KS07_WT or KS07_K/O virus (Figure 2-2). 
In full-length PB1-F2, the N66S mutation has been shown to contribute to the viral pathogenicity 
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and delaying type I interferon (IFN) response (Conenello et al., 2007; Schmolke et al., 2011). 
The type I IFN suppression activity of PB1-F2 is due to inhibition of the early interferon-
stimulated genes (ISGs) as well as decreasing mitochondrial membrane potential via interacting 
with the mitochondrial antiviral signaling protein (MAVS) (Conenello et al., 2011; Conenello et 
al., 2007; Varga et al., 2012). Our results confirm the findings of former studies that PB1-F2 66S 
is a virulence maker of IAV in mice. Consistent with previous studies, it could be possible that 
the N66S substitution in KS07 virus leads to enhanced IFN antagonist activity of the PB1-F2, 
thereby increasing the viral virulence.  
In pigs, previous studies using low virulent TR H3N2 SIVs have revealed that deletion of 
the PB1-F2 ORF or incorporation of the N66S mutation in the PB1-F2 ORF does not influence 
virus replication, shedding or pathogenicity in pigs (Deventhiran et al., 2015; Pena et al., 2012a). 
In contrast, the deletion of PB1-F2 expression or N66S substitution in virulent KS07 H1N1 virus 
has some degree of influence on pathogenicity in swine, i.e., both mutated viruses showed less 
efficient virus replication in lungs at 1 dpi and nasal shedding at 3 and 5 dpi (Figure 2-5B and C), 
and induced histopathologic lesions in both lung and trachea tissues from less infected pigs at 1 
dpi when compared to the KS07_WT virus (Table 2-1). One recent study demonstrated that 
swine IAVs express a very low level of PB1-F2 protein relative to human isolates (Buehler et al., 
2013). In particular, Buehler et al. showed that A/swine/Ohio/511445/2007 (H1N1), which has 
the highest nucleotide sequence identity (99.7% -99.9%) to the virus genome of KS07 virus (Ma 
et al., 2010), expressed PB1-F2 protein from less than 1% of the infected cells and PB1-F2 could 
not be detected in virus infected cells, suggesting that carrying a full-length PB1-F2 ORF does 
not serve as a predictor for sufficient PB1-F2 protein expression. This could explain why no 
significantly different phenotypes were observed between wild type and PB1-F2 knockout 
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viruses in pigs in this study or in former studies. The effect of PB1-F2 protein on virus 
replication and host immune response needs to be investigated in future studies when it is 
sufficiently expressed in SIV infected cells. 
The pro-inflammatory cytokine response is crucial for recruiting effector cells to the site 
of infection to clear virus. The PB1-F2 protein has been shown to influence viral pathogenicity 
by modulating the host innate immune response, which helps to promote lung inflammation 
(Alymova et al., 2014; Le Goffic et al., 2010). Our pig study showed that decreased levels of all 
cytokine/chemokines as well as significantly lower levels of IL-2, IL-4 and IL-12 at early time 
points (1 dpi) and significantly increased levels of GM-CSF, IFN-γ, IL-6 and IL-8 at later time 
points (3 or 5 dpi) were found in lungs of pigs infected with the KS07_WT compared to what 
were observed for the KS07_K/O (Figure 2-7). Downregulated and upregulated 
cytokine/chemokines at early and later time points seem to correlate with observed severity of 
microscopic lesions in the lung and trachea tissues in both KS07_WT and KS07_K/O groups 
(Figure 2-6 and Table 2-1). Our results suggested that PB1-F2 modulates host immune response 
in swine throughout the course of infection. These results are in disagreement with the findings 
of a  former study that showed PB1-F2 modulation of host immune responses only occurs shortly 
after infection (24 hpi) (Pena et al., 2012b). This discrepancy might be due to the difference in 
the virus strain used in the studies. In our study we used a virulent North American TR H1N1 
virus, rather than the 2009 pandemic H1N1 virus that contains Eurasian swine-origin NA and M 
genes. 
The presence of specific amino acid residues, known as inflammatory residues or 
cytotoxic residues, at the C-terminal region of the PB1-F2 protein are linked to increased 
pathogenicity and secondary bacterial infection (Alymova et al., 2011; Alymova et al., 2014; 
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Conenello et al., 2011; Conenello et al., 2007). The PB1-F2 sequence of KS07 contains only two 
pro-inflammatory residues (L62 and L82) and none of the cytotoxic motifs, whereas H5N1 
HPAIVs and all three pandemic IAVs from the last century (H1N1 1918, H2N2 1957 and H3N2 
1968) include three or more of the virulence genetic markers (Figure 2-8). In addition, the C-
terminal part of the PB1-F2 protein contains a mitochondrial targeting sequence (MTS) which 
allows the PB1-F2 protein to localize within the mitochondria (Gibbs et al., 2003; Yamada et al., 
2004). This localization allows PB1-F2 to interact with mitochondrial membrane-related proteins 
followed by mitochondrial permeability alteration resulting in the induction of apoptosis 
(Chanturiya et al., 2004; Zamarin et al., 2005). One recent report revealed that a translocated 
full-length PB1-F2 protein in the mitochondria attenuated the mitochondrial membrane potential 
which suppressed mitochondrial-mediated innate immunity, such as retinoic acid-inducible gene 
1 (RIG-I) signaling pathway, and also inhibited the activation of NLRP3 inflammasomes, while 
a truncated PB1-F2 protein which lacks a C-terminal region was diffused in cytoplasm and did 
not impact mitochondrial functions  (Yoshizumi et al., 2014).  Consistent with these findings, all 
of cytokine/chemokines at 1 dpi in lungs of pigs infected with the KS07_WT in our studies 
showed lower levels than those of pigs infected with the KS07_K/O (Figure 2-7). It is possible 
that full-length PB1-F2 expression in KS07_WT negatively regulated mitochondrial-mediated 
innate immunity and that may affect the secretion of cytokine/chemokines in virus infected pigs 
at early post infection time points.  
Another previous study demonstrated that different secondary structural forms were 
observed at the C-terminal region of the PB1-F2 protein based on amino acids sequences under 
membranous solution conditions. One continuous C-terminal α-helix was seen in less virulent 
strains, while a divided C-terminal α-helix was located in the PB1-F2 proteins of HPAIVs 
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(Solbak et al., 2013).  These structural differences at the C-terminal region of PB1-F2 may allow 
it to serve as different danger signals and induce different immune reactions in the host. It 
remains to be determined whether the KS07 PB1-F2 has the C-terminal α-helix structure and 
how that structure affects immune responses in different hosts.  
 2.5 Conclusions 
In summary, our data indicates that PB1-F2 expression in virulent H1N1 KS07 SIV has 
effects on virus replication and pathogenicity in the natural host, pigs, but not in mice. In 
addition, PB1-F2 expression modulates host immune responses in pigs and the substitution N66S 
in PB1-F2 plays a critical role in virulence in mice, while no effect was found in pigs. Our results 
provide new insights into the impact of PB1-F2 on virulence of IAVs in swine, and support PB1-
F2 as a virulence factor of IAV in a strain- and host-dependent manner.  
  
65 
Figure 2-1 Plaque morphology and growth kinetics of the recombinant influenza viruses 
 
Figure 2-1 (A) Plaque sizes formed by recombinant viruses in MDCK cells at 3 days post-
infection (dpi). (B) Growth kinetics of indicated recombinant viruses in MDCK or PK-15 cells 
infected at an MOI of 0.001.  Each data point on the curve indicates the means of the results in 
triplicate, and the error bars indicate standard errors of the mean (SEM).   
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Figure 2-2 Contribution of PB1-F2 to pathogenicity of recombinant KS07 in BALB/c mice 
Figure 2-2 (A) Average body weights of surviving mice in each group up to 14 dpi are represented 
as percentages of the original weight on day 0. a and b on the value point of each day address 
significant differences (p<0.05) between infected groups (a: KS07_WT and KS07_N66S, b: 
KS07_K/O and KS07_N66S). The error bars indicate standard errors of the mean (SEM). (B) 
Survival rate of mice infected with indicated viruses. KS07_N66S infected group showed 
significantly higher mortality rate compared to KS07_WT infected group (p<0.005 by log-rank 
test).   
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 Figure 2-3 Lung virus replication and histopathological scores of mouse study  
 Figure 2-3 (A) Lung virus titers of infected mice were determined at 3 and 7 dpi by calculating 
the 50% tissue culture infective dose (TCID50)/ml in MDCK cells. (B) Microscopic lung scores 
are presented as average scores ± SEM of three mice in each group at 3 and 7 dpi. The asterisks 
(*) indicate a statistically significant difference between groups (p<0.05). The error bars represent 
standard errors of the mean (SEM).  
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Figure 2-4 H&E and IHC staining of mouse lung sections at 7 dpi  
 Figure 2-4 H&E stained sections of mouse lungs infected with indicated viruses at 7 dpi showed 
typical influenza pneumonia. Pictures are representative sections at 40× magnification. In the 
mock infected control, no lesions are present and there is no antigen deposition in the airway 
epithelium. In KS07_WT, there are areas of multifocal mild interstitial pneumonia (asterisk) and 
there is cuffing of bronchioles and vessels by lymphocytes and plasma cells. In KS07_K/O and 
KS07_N66S, there is mild epithelial hyperplasia (arrow), mild lymphocytic peribronchiolar 
cuffing (asterisk), and small amounts of fibrin and increased alveolar macrophages in alveolar 
lumina. IHC staining of lung sections were also conducted to detect influenza virus antigen using 
an anti-influenza A NP mAb (Brown staining). 
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Figure 2-5 Contribution of PB1-F2 to pathogenicity of recombinant KS07 in pigs  
  Figure 2-5 (A) Macroscopic lung lesions of infected pigs are shown as the mean percentage ± 
SEM of gross lesions of three pigs in each group at 1, 3 and 5 dpi. Mean of virus titers in 
bronchoalveolar lavage fluid (BALF) (B) and in nasal swabs (C) of infected pigs on the days 
indicated. The number of pigs with positive virus isolation out of the total number of tested pigs is 
shown above of each bar (B, C). 
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Figure 2-6 H&E staining of pig lung and trachea sections at 3 dpi  
Figure 2-6 Lung and trachea sections of pigs infected with indicated viruses at 3 dpi were stained 
with H&E. Pictures are representative sections at 40× magnification. In the mock infected control, 
the lung is normal which is demonstrated by normal airway epithelium and alveoli, and tracheal 
epithelium has goblet cells and cilia (arrow). In KS07_WT, the bronchiole is surrounded by 
lymphocytes and plasma cells which extend into the alveolar septa (interstitial pneumonia) 
(asterisk). In KS07_K/O, there is flattening of airway epithelium (arrow) and cuffing by 
peribronchiolar cuffing by lymphocytes (asterisk). The trachea in this pig has diffuse loss of cilia 
and goblet cells consistent with early degeneration due to influenza (arrow). In KS07_N66S, there 
is cuffing of bronchioles and vessels by lymphocytes and plasma cells (asterisk) and the trachea 
lacks goblet cells but has a normal layer of cilia.  
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Figure 2-7 Cytokine/chemokine levels in BALF of infected and control pigs  
Figure 2-7 Expressions of the indicated 12 porcine cytokines/chemokines in BALF were 
quantified using the Luminex technology. Data represent the average values ± SEM of three pigs 
in each group on the days indicated. Significant differences (p<0.05) between two groups are 
indicated with dashed brackets. The # represents a statistically significant difference with the 
mock infected control group. The asterisks (*) indicate a statistically significant difference 
between virus infected groups (*: p<0.05. **: p<0.01 and ***: p<0.001).  
IL-6
1 dpi 3 dpi 5 dpi
0.00
0.05
0.10
0.15
0.20
#
#
#
#
#
***
***
**
*
n
g
/m
L
IL-8
1 dpi 3 dpi 5 dpi
0.0
0.2
0.4
0.6
0.8
#
#
*
*
n
g
/m
L
IFN-
1 dpi 3 dpi 5 dpi
0.0
0.2
0.4
0.6
0.8
#
*
*
n
g
/m
L
IL-1
1 dpi 3 dpi 5 dpi
0.00
0.02
0.04
0.06
#
*n
g
/m
L
IL-1
1 dpi 3 dpi 5 dpi
0.0
0.2
0.4
0.6
0.8
1.0
#
#
#
# #
*
n
g
/m
L
TNF-
1 dpi 3 dpi 5 dpi
0.000
0.005
0.010
0.015
0.020
0.025
KS07_WT
KS07_K/O
KS07_N66S
Control
n
g
/m
L
IL-4
1 dpi 3 dpi 5 dpi
0.00
0.05
0.10
0.15
0.20
0.25
#
#
#
#* *
*
*
*
n
g
/m
L
GM-CSF
1 dpi 3 dpi 5 dpi
0.00
0.05
0.10
0.15
0.20
0.25
#
**
n
g
/m
L
IL-12
1 dpi 3 dpi 5 dpi
0.00
0.05
0.10
0.15
#
#
#
*
n
g
/m
L
IL-2
1 dpi 3 dpi 5 dpi
0.00
0.02
0.04
0.06
0.08
0.10 #
##
##
* *
n
g
/m
L
IL-10
1 dpi 3 dpi 5 dpi
0.00
0.02
0.04
0.06
0.08
#
#
#
***
*
n
g
/m
L
IL-18
1 dpi 3 dpi 5 dpi
0
1
2
3
4
5
#
#
*
n
g
/m
L
72 
Figure 2-8 Alignment of C-terminal sequences of PB1-F2 from selected IAVs 
Figure 2-8 Amino acid sequences of the C-terminal region in KS07 PB1-F2 protein was aligned to 
those of the last century pandemic strains (H1N1 1918, H2N2 1957 and H3N2 1968), a previously 
characterized strain (PR8 H1N1), and one H5N1 HPIAV. Amino acid residues in red or blue 
letters have been identified as inflammatory residues (L62, R75, R79 and L82) or cytotoxic 
residues (I68, L69 and V70), respectively. Numbers with asterisks indicate amino acid positions 
according to PB1-F2 numbering. 
                                   62           68 69 70        75       79     82 
                                      *           * * *         *       *     * 
KS07                         [60] P W L S L K N P T Q G Y L R I H A L K Q W K L S N K Q G W I N * [90] 
A/Brevig_Mission/1/1918(H1N1)[60] Q W L S L R S P T P V S L K T R V L K R W R L F S K H E W T S * [90] 
A/Puerto_Rico/8/1934(H1N1)   [60] Q W L S L R N P I L V F L K T R V L K R W R L F S K H E *       [87] 
A/Guiyang/1/1957(H2N2)       [60] Q W L S L K N P T Q E S L K T R V L K R W K L F N K Q E W T N * [90] 
A/Hong_Kong/1/1968(H3N2)     [60] Q W L S L K N P T Q G S L K T R V L K R W K L F N K Q G W T D * [90] 
A/Hong_Kong/156/97(H5N1)     [60] Q W L S L K N P T Q D S L K T H V L K R W K L S S K R E W I S * [90] 
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Table 2-1 Microscopic lesions of respiratory tract and lungs in infected and control pigs on days 1, 3, and 5 dpi 
Virus 
No. of pigs with microscopic lesions/ No. of the total euthanized pigs on the indicated days (microscopic lesion score) 
1 dpi  3 dpi  5 dpi 
Lung Trachea NT  Lung Trachea NT  Lung Trachea NT 
KS07_WT 3/3 (0.80±0.23) 3/3 (0.50±0.00) 1/3 (0.50)  1/3 (1.60) 2/3 (1.25±0.20) 1/3 (0.50)  1/3 (1.60) 0/3  0/3  
KS07_K/O 2/3 (1.70±0.90) 1/3 (1.00) 2/3 (0.50±0.00)  3/3 (1.33±0.29) 1/3 (0.50) 1/3 (0.50)  2/3 (0.7±0.41) 1/3 (1.00) 0/3  
KS07_N66S 0/3  1/3 (0.50) 2/3 (0.50±0.00)  1/3 (1.60) 1/3 (0.50) 1/3 (0.50)  0/3  0/3  0/3  
Control 0/3  0/3  0/3   0/3  0/3  0/3   0/2  0/2  0/2  
Results are presented as the number of pigs with microscopic lesions out of the total number of pigs on the indicated days. Three different 
tissues in the respiratory tract were evaluated. 
 
Numbers in parentheses indicate the mean score of microscopic lesions ± standard errors of the 
mean (SEM). NT, nasal turbinate. 
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Chapter 3 - Impacts of different expressions of PA-X protein on 
2009 pandemic H1N1 virus replication, pathogenicity and host 
immune responses 
Abstract: 
A new influenza virus protein, PA-X, is expressed by ribosomal frameshifting from PA 
gene. Although several studies have described the function of PA-X, the impact of different 
expressions of PA-X protein including full-length, truncated or PA-X deficient forms on viral 
pathogenicity and host response remains unclear. Herein, two mutated viruses were generated 
using reverse genetics in the genetic background of H1N1 A/California/04/2009 (CA09) which 
expresses a truncated PA-X protein: one is CA09_PA-X_Full which encodes a full-length PA-X, 
and the other is CA09_PA-X_K/O in which the PA-X is knocked out. The CA09_PA-X_Full 
virus grew more efficiently in MDCK and A549 cells than both CA09_WT and CA09_PA-
X_K/O viruses. In addition, expression of either full-length or truncated PA-X protein 
significantly increased viral polymerase activity and suppressed co-transfected gene expression 
in 293T cells when compared to deficient PA-X expression. The CA09_PA-X_K/O showed 
attenuated virulence in mice compared to the other two viruses. However, CA09_PA-X_K/O 
induced more severe lung damage with higher expression of pro-inflammatory cytokines in 
mouse lungs than the other two viruses. The results indicate that expression of either full-length 
or truncated PA-X protein enhanced viral replication and pathogenicity as well as reduced the 
host innate immune response by host shutoff activity when compared to CA09_PA-X_K/O and 
that full-length PA-X expression exhibited a greater effect than the truncated PA-X form. Our 
results provide novel insights of PA-X on viral replication and host immune responses. 
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 3.1 Introduction 
Influenza A virus (IAV) is a single-stranded negative sense RNA virus that belongs to the 
Orthomyxoviridae family. It contains eight segmented viral genomes and was thought to encode 
10 viral proteins (PB2, PB1, PA, HA, NP, NA, M1, M2, NS1 and NS2). Recently, several new 
influenza viral proteins have been discovered, such as PB1-F2 (Chen et al., 2001), PB1-N40 
(Wise et al., 2009), PA-X (Jagger et al., 2012), NS3 (Selman et al., 2012), PA-N155, PA-N182 
(Muramoto et al., 2013), M42 (Wise et al., 2012), and PB2-S1(Yamayoshi et al., 2016). Among 
these, the PA-X protein is translated through a +1 ribosomal frameshifting event in segment 3, 
the PA gene. This PA-X protein has the identical N-terminal 191 amino acids (aa) to PA protein 
and a PA-X unique C-terminal domain of 41 or 61 aa by alternative translation (Jagger et al., 
2012). Expression of PA-X protein in most IAVs is the full-length form with 61 aa in the C-
terminal domain, while both the 2009 pandemic H1N1 (pH1N1) virus and triple-reassortant 
swine influenza viruses circulating in North American swine herds express a truncated PA-X 
protein with only 41 aa due to a stop codon at position 42 in the C-terminal domain (Jagger et 
al., 2012; Shi et al., 2012). Since PA-X shares the N-terminal endonuclease domain with PA, it 
provides the host shutoff activity for PA-X to destroy the host mRNA and suppress host protein 
synthesis (Desmet et al., 2013; Jagger et al., 2012). Although PA and PA-X have the same N-
terminal domain, PA-X has been shown to have a stronger endonucleolytic activity than PA, 
indicating that the unique C-terminal part of PA-X is also responsible for shutoff activity 
(Bavagnoli et al., 2015; Desmet et al., 2013; Hayashi et al., 2016; Oishi et al., 2015). 
Recently, many studies have described the effects of PA-X on viral replication and 
pathogenicity. Jagger et al. reported that PA-X expression reduced the viral pathogenicity of 
the1918 pandemic H1N1 virus, even if PA-X had no effect on viral replication (Jagger et al., 
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2012). Two other reports also showed that loss of PA-X expression increased viral replication 
and pathogenicity of 2009 pH1N1 virus and H5N1 highly pathogenic avian influenza virus 
(HPAIV) in vitro and in vivo when compared to the wild type viruses that express PA-X (Gao et 
al., 2015b; Hu et al., 2015). In contrast to previous reports, recent studies showed that PA-X 
deficient 2009 pH1N1 and H9N2 viruses attenuated viral pathogenicity in mice compared to the 
wild type virus (Gao et al., 2015c; Hayashi et al., 2015). Other studies also investigated the 
contribution of 20aa at the C-terminal end of PA-X to viral replication and virulence by 
comparing PA-X full-length form with the truncated form. Gao et al. demonstrated that three 
different IAVs (2009 pH1N1, H5N1 HPAIV and H9N2 AIV) increased viral replication and 
pathogenicity when the viruses express the full-length PA-X protein with 61aa in the C-terminal 
domain compared to those with a truncated PA-X expression (Gao et al., 2015a), whereas triple-
reassortant H1N2 swine influenza virus with truncated PA-X enhanced viral pathogenicity and 
replication in pigs (Xu et al., 2016).  
The host shutoff activity of PA-X protein is expected to weaken the host antiviral 
response by inhibiting host protein synthesis including immune related gene expression. Previous 
studies reported that PA-X deficient virus markedly upregulated expression levels of apoptosis, 
inflammation and immune response related genes in mice or chicken lungs, using global gene 
expression profiling (Hu et al., 2015; Jagger et al., 2012). Recently, Hayashi et al. found that 
PA-X deficient virus induced a significantly greater amount of IFN-β mRNA as well as more 
anti-hemagglutinin neutralizing antibodies in mice when compared to the wild type virus 
(Hayashi et al., 2015). Therefore, it suggests that PA-X is an important accessory protein of IAV 
as an immune modulator and virulence factor.  However, the detailed underlying mechanisms of 
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PA-X function and the effects of different expressions of PA-X protein on viral pathogenicity as 
well as host immune response remain unclear.  
In this study, we used 2009 pH1N1 A/California/04/2009 (CA09) virus which expresses 
a truncated PA-X protein and its two mutated viruses generated by reverse genetics to investigate 
the impacts of three different expressions of PA-X protein (full-length, truncated and PA-X 
deficient forms) on viral replication, pathogenicity and host innate immune response. 
 3.2 Materials and Methods 
 Cells 
Human embryonic kidney (293T) cells were cultured in Opti-modified Minimal Essential 
Medium (MEM) supplemented with 10% fetal bovine serum (FBS) (Hyclone) and 1% antibiotic-
antimycotic (Gibco). Madin-Darby canine kidney (MDCK) cells were grown in MEM containing 
5% FBS, 1% antibiotic-antimycotic, 2mM L-glutamine (Gibco) and 1X MEM vitamin solution 
(Gibco). Human lung adenocarcinoma epithelial (A549) cells were maintained in Dulbecco's 
modified Eagle medium (DMEM) supplemented with 5% FBS, 2mM L-glutamine, 1X MEM 
vitamin solution and 1% antibiotic-antimycotic. MEM infecting media containing 0.3% bovine 
serum albumins (BSA) (Sigma-Aldrich), 1% antibiotic-antimycotic and 1μg/ml TPCK-treated 
trypsin (Sigma-Aldrich) were used for virus infection of cells.  
 Plasmid constructions 
Eight-plasmid reverse genetics for the 2009 pH1N1 A/California/04/2009 (CA09) virus 
has been established and described in our previous study (Qiao et al., 2012). Eight-gene 
segments of CA09 virus were cloned into a pHW2000 vector (Hoffmann et al., 2000; Hoffmann 
et al., 2001). To generate the CA09_PA-X_Full virus that expresses a full-length PA-X, a single 
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amino acid substitution from UAG (stop) to UGG (tryptophan) at position 42 in the C-terminal 
domain of PA-X protein was introduced based on pHW2000-PA_WT using a GeneArt® site-
directed mutagenesis kit (Invitrogen) according to the manufacturer’s instructions (Figure 3-1). 
The resulting plasmid was named pHW2000-PA_PA-X_Full. To construct the PA-X deficient 
virus that does not express truncated or full-length PA-X, three nucleotide mutations in 
frameshifting motif were introduced from UCC UUU CGU to UCC UUC AGA based on 
pHW2000-PA_WT by site-directed mutagenesis to prevent PA-X expression as described 
previously (Figure 3-1) (Jagger et al., 2012). The resulting plasmid was named pHW2000-
PA_PA-X_K/O. None of the mutations altered the PA open reading frame (ORF) as silent 
mutations which were confirmed by sequencing. To investigate expression of different PA-X 
forms, the coding regions of proposed different PA-X forms were cloned into pCAGGS vector 
(kindly provided by Dr. Adolfo García-Sastre, Mount Sinai School of Medicine, NY, USA) and 
the resulting three plasmids were named pCAGGS_PA-X_WT, pCAGGS_PA-X_Full and 
pCAGGS_PA-X_K/O. To investigate effects of different expressions of PA-X protein on the 
polymerase activity, ORFs of wild type and two mutated PA genes as well as PB1, PB2 and NP 
genes of the CA09 virus were cloned into pCAGGS vector (. The resulting plasmids were 
pCAGGS_PA_PA-X_WT, pCAGGS_PA_PA-X_Full, pCAGGS_PA_PA-X_K/O, 
pCAGGS_PB1, pCAGGS_PB2, and pCAGGS_NP that were confirmed by sequencing. 
 Rescue of wild type and mutated CA09 H1N1 recombinant viruses 
Wild type (CA09_WT), PA-X knock-out (CA09_PA-X_K/O) and full-length PA-X 
expression (CA09_PA-X_Full) CA09 viruses were generated by reverse genetics using the eight-
plasmid system. To rescue CA09_PA-X_K/O and CA09_PA-X_Full viruses, the pHW2000-
PA_WT was replaced with pHW2000-PA_PA-X_K/O or pHW2000-PA_PA-X_Full, 
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respectively. Briefly, MDCK and 293T cells were co-cultured in 6-well plates and transfected 
with eight constructed pHW2000 plasmids encoding viral genomic RNA segments using 
Lipofectamine 2000 (Invitrogen). After 48 hours post transfection, supernatants were collected 
and passaged three times on MDCK cells. The rescued viruses were confirmed by sequencing 
(Sanger DNA Sequencing service provided by GENEWIZ).   
 Replication kinetics 
To evaluate the growth kinetics of recombinant viruses, MDCK and A549 cells were 
cultured in 12-well plates and infected with each virus at a multiplicity of infection (MOI) of 
0.01 in triplicate. Supernatants were collected at 12, 24, 36 and 48 hours post-infection (hpi). 
Virus titers were determined by calculating the 50% tissue culture infective dose (TCID50)/ml in 
MDCK cells. The plaque assay was performed to compare the size of plaques formed by each 
recombinant virus on MDCK cells.   
 Western blot analysis 
Confluent 293T cells were transfected with pCAGGS_PA-X_WT, pCAGGS_PA-X_K/O 
or pCAGGS_PA-X_Full using Lipofectamine 2000 (Invitrogen). Mock control was transfected 
with empty pCAGGS plasmid. At 18 hours post-transfection, cells were washed twice with 
phosphate-buffered saline (PBS) and total cell lysates were extracted using CelLytic M cell lysis 
reagent according to the manufacturer’s instructions (Sigma-Aldrich). The extracted cell lysates 
were loaded to 4-12% Bis-Tris polyacrylamide gel (Invitrogen) and transferred onto a 
polyvinylidene difluoride (PVDF) membrane using an electrophoresis system (Invitrogen). Non-
specific binding on the blot was blocked using 5% skim milk dissolved in Tris-buffered saline 
with 0.05% Tween-20 (TBST) buffer for one hour at room temperature and then incubated with 
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a primary monoclonal antibody against PA-X (diluted 1:1000, kindly provided by Dr. Toru 
Takimoto, University of Rochester Medical Center, NY, USA) or β-actin (1:500 dilution, Santa 
Cruz) overnight at 4⁰C. The membrane was washed three times for five minutes each in TBST 
buffer and was incubated with horseradish peroxidase (HRP)-conjugated polyclonal rabbit anti-
mouse immunoglobulins (diluted 1:1000, Dako). Target proteins were detected using 
SuperSignal West Femto Maximum Sensitivity Substrate according to the manufacturer’s 
protocol (Thermo Scientific). 
 Viral RNP polymerase assay 
The effects of different expressions of PA-X protein on polymerase activity were 
determined using ribonucleoprotein (RNP) minigenome assay as described previously (Bortz et 
al., 2011). Briefly, a reporter minigenome plasmid (pPolI-NS-Luc) that contains the firefly 
luciferase gene flanked by the noncoding regions of influenza A virus NS gene with a 
polymerase I (Pol I) promoter was used. Confluent 293T cells were co-transfected with pPolI-
NS-Luc (100ng) and four pCAGGS vectors encoding PB2, PB1, NP and PA (PA_PA-X_WT, 
PA_PA-X_Full or PA_PA-X_K/O) (the volume of the PB2, PB1, PA and NP plasmids used 
were 50ng, 100ng, 100ng and 500ng respectively) along with pSV-Renilla (50 ng) (pRL-SV40, 
Promega) carrying the Renilla luciferase gene as an internal control. As a negative control, cells 
were transfected with the same aforementioned plasmids mixture except the plasmid expressing 
PA. After 24 hours post-transfection, cells were collected using passive cell lysis buffer and 
luciferase activity was determined using a dual-luciferase reporter assay system according to the 
manufacturer’s instructions (Promega). The relative polymerase activity was quantified by 
comparing to negative control cells which were transfected with pCAGGS blank plasmid instead 
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of PA expression plasmid, after normalizing it to the Renilla luciferase internal control. Each co-
transfection experiment was performed in triplicate. 
 GFP expression assay 
Confluent 293T cells were co-transfected with 500ng of pEGFP-N1 (Clontech) and 
500ng of each PA plasmid that expresses different PA-X forms (pCAGGS_PA-WT, 
pCAGGS_PA_PA-X_K/O and pCAGGS_PA_PA-X_Full). After 24 hours post-transfection, 
cells were lysed with passive lysis buffer and the fluorescent intensity was measured using 
FLUOstar Omega (BMG LABTECH). The fluorescent intensity was standardized to the 
pCAGGS empty vector transfected control cells. The expressed GFP proteins and β-actin were 
detected from total cell lysates by western blotting to determine the relative expression of GFP 
protein using anti-GFP antibody (1:200 dilution, Santa Cruz) or anti-β-actin antibody (1:500 
dilution, Santa Cruz). The detected protein bands were quantified using densitometry with 
AlphaEase FC Software (Alpha Innotech). The GFP protein expressions were normalized to β-
actin expression. 
 Pathogenicity study in mice 
A total of 56 six-week-old female BALB/c mice were randomly divided into four groups 
(14 mice/group). Mice from each group were inoculated intranasally (IN) with 3.75 x 10
5 
TCID50 
of each virus in a volume of 50 μl under slight anesthesia with isoflurane. For the control group, 
mice were mock-infected with 50 μl of virus-free MEM. Mice were monitored daily for clinical 
signs and weighed daily until 14 days post infection (dpi). Mice that lost more than 25% of their 
original body weight were humanly euthanized. Three mice from each group were euthanized at 
3 and 7 dpi. Lungs were collected from each mouse to assess virus replication, cytokine gene 
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expressions and histopathological analysis. For virus titration, 10% lung homogenates were 
made using fresh MEM with 1% antibiotic-antimycotic, and virus titers in the lung homogenates 
were determined on MDCK cells. 
 qRT-PCR 
Total RNAs from lung homogenates were extracted using the RNeasy Plus Mini kit 
according to the manufacturer’s protocol (Qiagen). The cDNA was synthesized from 1 μg of 
total RNA of each sample using the SuperScript III Reverse Transcriptase (Invitrogen) with 
Oligo(dT)20 by reverse transcription reaction.  The gene specific primers and probes were 
obtained from the TaqMan Gene Expression Assays (Applied Biosystems). The quantitative real-
time PCR assays (qRT-PCR) were performed with equal volumes of cDNA from each sample 
and gene specific primers and probes using the TaqMan Fast Universal PCR Master Mix 
(Applied Biosystems). Amplification was conducted using the CXF96 Touch real-time PCR 
system (Bio-Rad) with the following cycle program: 1 cycle at 95ºC for 10 min, followed by 45 
cycles at 95ºC for 15 s and 60ºC for 1 min. The expression fold change of each group was 
calculated relative to control group after normalization to 18S ribosomal RNA internal control 
using 2
-ΔΔCt
 method (Livak & Schmittgen, 2001).  Each experiment was performed in triplicate. 
 Histopathology and immunohistochemistry 
Lung samples from mice were fixed in 10% neutral buffered formalin and processed by 
the histopathology and immunohistochemistry laboratory of the Kansas State Veterinary 
Diagnostic Laboratory (KSVDL). A board-certified veterinary pathologist evaluated 
histopathological lesions of routinely processed hematoxylin and eosin (H&E) stained tissues. 
For the lung microscopic lesions in mice, lungs were graded on the following seven criteria: 
Subjective percentage of lung involved in the histological section examined (4 point scale of 1-
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4); airway epithelial necrosis, neutrophilic airway inflammation, peribronchiolar lymphocyte 
cuffing, interstitial pneumonia, airway epithelial hyperplasia (all on a 3 point scale of 1-3); and 
lastly the presence and absence of hyaline membranes (2 point scale, 0=absent and 1=present). 
Immunohistochemistry (IHC) staining for mouse lungs was conducted to detect influenza virus 
antigen in tissues using an anti-influenza A H1N1 rabbit polyclonal antibody. Antigen retrieval 
was performed using EDTA at pH 9.0 for 10 minutes at 100 ºC. The antibody was diluted 1:4000 
and detected with the Leica Bond Polymer Refine Detection Kit on the Leica Bond-Max. 
 Statistical analysis 
For statistical analysis among groups, analysis of variance (ANOVA) test was used in 
GraphPad Prism version 5.0 (GraphPad Software). For comparisons of survival curves, a log-
rank test was performed. A p value of 0.05 or less was considered statistically significant. 
 3.3 Results 
 Generation of wild type pH1N1 and mutated viruses expressing different PA-X forms 
To investigate the effects of three different expressions of PA-X protein on viral 
pathogenicity and host innate immune response, we rescued a recombinant wild type 
A/California/04/2009 (CA09_WT) virus that expresses truncated PA-X protein with 232aa and 
its two mutant viruses (CA09_PA-X_K/O and CA09_PA-X_Full) using reverse genetics. 
CA09_PA-X_Full virus expressing a full-length PA-X with 252aa was generated by substituting 
stop codon (UAG) with tryptophan (UGG) at the 42aa position in the C-terminal domain of PA-
X (Figure 3-1A). CA09_PA-X_K/O virus, which does not express the PA-X, was generated 
through mutations in the frameshift motif from UUU CGU to UUC AGA according to the 
previous study (Jagger et al., 2012) to prevent the PA-X expression (Figure 3-1A). Due to the 
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very low frameshifting efficiency (~1.3%) of PA-X gene (Jagger et al., 2012), it is very difficult 
to detect PA-X expression in virus infected cells. To confirm that the generated viruses were able 
to express the expected PA-X, we transfected 293T cells with different PA-X ORF encoding 
plasmids (pCAGGS_PA-X_WT, pCAGGS_PA-X_Full or pCAGGS_PA-X_K/O) to detect 
expressed PA-X proteins. Both truncated PA-X (232aa) and full-length PA-X (252aa) were 
detected by western blotting analysis in each plasmid transfected cells, while no PA-X was 
detected in transfected cells with pCAGGS_PA-X_K/O plasmid that the PA-X is proposed to be 
knocked out (Figure 3-1B). 
 PA-X expression increases virus replication and polymerase activity in vitro 
To further characterize wild type and its mutated viruses in vitro, we first performed a 
plaque assay in MDCK cells. Both CA09_PA-X_K/O and CA09_PA-X_Full mutated viruses as 
well as the CA09_WT formed similar small size of plaques in MDCK cells (Figure 3-2A). Next, 
we examined virus replication kinetics of three viruses in MDCK and A549 cells. CA09_WT 
and its two mutated viruses replicated efficiently in both MDCK and A549 cells. In contrast, 
CA09_PA-X_Full virus grew to a higher titer than the other two viruses (CA09_PA-X_WT and 
CA09_PA-X_K/O) in both cell lines and a significant higher titer was observed at 24 and 36 hpi 
in A549 cells (Figure 3-2B). The viral yields of PA-X deficient virus (CA09_PA-X_K/O) was 
significantly lower than both viruses expressing either a full-length or truncated PA-X 
(CA09_PA-X_Full and CA09_PA-X_WT) in MDCK cells (Figure 3-2B). The data indicates that 
PA-X expression enhances virus replication, particularly when the CA09 virus expresses the full-
length PA-X.  
To determine whether PA-X expression enhances virus replication through effects on the 
viral RNA polymerase activity, a minigenome assay was performed by measuring the reporter 
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gene expression levels which indirectly indicates the viral polymerase activity. Transfection of 
combination with the plasmid pCAGGS-PA_PA-X_K/O showed significantly lower polymerase 
activity when compared to those with either pCAGGS-PA_PA-X_WT or pCAGGS-PA_PA-
X_Full, with 2.0 and 3.7 fold differences, respectively (Figure 3-2C). In addition, the polymerase 
complex with the pCAGGS-PA_PA-X_Full combination displayed the strongest polymerase 
activity (Figure 3-2C). In summary, PA-X expression increases viral RNA polymerase activity, 
thereby resulting in enhanced viral replication. 
 PA-X expression inhibits co-transfected gene expression 
Recent studies revealed that PA-X protein is involved in the shutoff of host protein 
synthesis (Desmet et al., 2013; Jagger et al., 2012).  To compare the contribution of different 
expressions of PA-X protein to shutoff activity, 293T cells were co-transfected with eGFP 
expression plasmid and individual PA expression plasmids (pCAGGS_PA-WT, 
pCAGGS_PA_PA-X_Full, or pCAGGS_PA_PA-X_K/O) for 24h. Relative GFP expression 
levels were determined by measuring relative fluorescence intensity and western blotting 
analysis. The reductions of GFP fluorescence intensity were observed from the cells co-
transfected with PA expression plasmids (pCAGGS_PA-WT, pCAGGS_PA_PA-X_Full, or 
pCAGGS_PA_PA-X_K/O); approximately 46%, 57% or 28% of decreased fluorescence signals 
were found  when compared to the control, respectively (Figure 3-3A and B).  The GFP protein 
expression levels were also reduced by 21%, 52% and 7%, respectively, in the presence of 
pCAGGS_PA-WT, pCAGGS_PA_PA-X_Full and pCAGGS_PA_PA-X_K/O, when compared 
to transfection with an empty pCAGGS vector (Figure 3-3C). In the presence of both full-length 
and truncated PA-X, the GFP expression levels were significantly suppressed in contrast to the 
PA-X deficient condition (Figure 3-3B and C). Furthermore, the GFP expression was markedly 
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reduced in cells co-transfected with pCAGGS_PA_PA-X_Full compared to co-transfection with 
either pCAGGS_PA-WT or pCAGGS_PA_PA-X_K/O (Figure 3-3B and C). These results 
indicate that full-length PA-X in CA09 virus has the most significant effect on shutoff activity of 
co-expressed protein synthesis, while loss of PA-X results in decreasing the shutoff ability. 
 PA-X expression increases virus replication and pathogenicity in mice 
To investigate the effect of different expressions of PA-X protein on virus pathogenicity 
in vivo, BALB/c mice were intranasally inoculated with 3.75 x 10
5 
TCID50 of each virus and 
monitored daily. Control animals did not show any clinical signs during the study. All infected 
mice in each group displayed clinical signs such as depression, less activities and obvious weight 
loss starting at 3 dpi when compared to the control animals. However, both PA-X expression 
viruses (CA09_PA-X_WT and CA09_PA-X_Full) induced more severe body weight loss 
(80.5% and 78.4% by 7 dpi and 8 dpi, respectively) than CA09_PA-X_K/O virus (body weight 
loss to 85.5% by 7 dpi) (Figure 3-4A). All mice infected with the CA09_PA-X_K/O virus 
survived, whereas the CA09_PA-X_Full virus caused 25% mortality and the CA09_PA-X_WT 
virus resulted in 12.5% mortality in infected animals (Figure 3-4B). Virus titers in mouse lungs 
infected with either CA09_PA-X_WT or CA09_PA-X_Full were higher than those infected with 
the CA09_PA-X_K/O at 3 dpi (Figure 3-5A), and a significant difference in virus titers was 
observed between the CA09_PA-X_Full and CA09_PA-X_K/O infected groups at 3 dpi. In 
contrast, a similar virus titer in mouse lungs was found in three infection groups at late time point 
(7 dpi) (Figure 3-5A).  
Histopathological analysis showed that no lung lesions were found in control mice, while 
animals from three infection groups exhibited lung damages at both 3 and 7 dpi (Figure 3-5B). 
Lesions consisted of varying degrees and percentage of lung affected with neutrophilic 
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bronchiolitis, segmental loss of bronchiole epithelium, cuffing of bronchioles by lymphocytes 
and interstitial pneumonia (expansion of alveolar septa by histocytes) (Figure 3-6). 
Histologically, lung lesions varied in severity depending on dpi and the infected virus. At 3 dpi, 
both CA09_PA-X_WT and CA09_PA-X_Full viruses induced less histopathological lung 
lesions than the CA09_PA-X_K/O virus (Figure 3-5B and Figure 3-6). Furthermore, a significant 
difference in lung lesions was found between CA09_PA-X_K/O and CA09_PA-X_Full virus 
infected groups (Figure 3-5B). More severe lung damage was observed in both CA09_PA-
X_WT and CA09_PA-X_Full infected mice at 7 dpi than at 3 dpi, whereas a similar lung lesion 
score was seen in CA09_PA-X_K/O infected mice at both days. Influenza antigens were 
detected in bronchiole epithelium and pneumocytes in infected mice using the H1N1 polyclonal 
antibody by immunohistochemistry analysis (Figure 3-6). Control mice had no staining in the 
lung by immunohistochemistry analysis (Figure 3-6). 
 PA-X expression suppresses the early inflammatory response in lungs of infected mice 
To investigate the impact of different expressions of PA-X protein on the host antiviral 
immune response, expression of representative cytokine genes related with the inflammatory 
response in lungs of infected mice was determined. Overall, CA09_PA-X_K/O virus induced 
stronger cytokine responses than both CA09_WT and CA09_PA-X_Full virus in mice at 3 dpi 
(Figure 3-7). In particular, CA09_PA-X_Full virus significantly reduced the gene expression 
levels of TNF-α, IL-1β, IL-6 and IL-12 when compared to CA09_PA-X_K/O virus at 3 dpi 
(Figure 3-7). However, all three viruses induced comparable levels of gene expressions of IL-1β, 
IL-6, IL-12 and IFN-β at the late time point (7 dpi). At 7 dpi, IFN-α, IFN-β and IFN-γ were 
highly expressed, while lower levels of  gene expressions of TNF-α, IL-1β, IL-6 and IL-12 were 
observed in infected mice with each virus compared to the early infection time point (3 dpi). 
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Taken together, the PA-X deficient virus elicited stronger cytokine response in lungs of infected 
mice at the early time point (3 dpi) than both PA-X expression viruses. Moreover, all tested 
cytokines and IFNs were more diminished in animals infected with CA09_PA-X_Full virus in 
contrast to those infected with CA09_WT expressing a truncated PA-X at the early time point (3 
dpi).  
 3.4 Discussion 
Since the PA-X protein was identified, multiple functions including effects on the viral 
virulence and modulation of the host immune response (Gao et al., 2015b; Gao et al., 2015c; 
Hayashi et al., 2015; Hu et al., 2015; Jagger et al., 2012) and suppression of host protein 
synthesis by strong host shutoff activity (Desmet et al., 2013; Hayashi et al., 2015; Jagger et al., 
2012) have been described. Furthermore, several studies compared the roles of full-length and 
truncated PA-X proteins in viral pathogenicity and endonuclease activity (Bavagnoli et al., 2015; 
Gao et al., 2015a; Xu et al., 2016). In contrast to previous studies, we investigated the 
contribution of three different expressions of PA-X protein (full-length, truncated and PA-X 
deficient forms) in 2009 pH1N1 virus which expresses truncated PA-X protein to viral 
replication, pathogenicity and host immune response. Our results showed that the expression of 
either full-length or truncated PA-X enhanced viral replication and pathogenicity of CA09 virus 
in cells as well as in mice and polymerase activity in vitro in contrast to the PA-X deficient 
expression (Figure 3-2 and Figure 3-4). Furthermore, the full-length PA-X expression resulted in 
more efficient replication in cells, higher virulence in mice and higher polymerase activity when 
compared to the truncated PA-X expression (Figure 3-2 and Figure 3-4). Our results are 
consistent with former findings that full-length PA-X in pH1N1, H5N1 and H9N2 viruses  
enhanced virus replication in cells and pathogenicity in mice compared to corresponding viruses 
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with truncated PA-X (Gao et al., 2015a). In addition, wild type 2009 pH1N1 virus with truncated 
PA-X expression showed increased viral growth in cells and virulence in mice compared to PA-
X deficient virus (Hayashi et al., 2015). These results indicate that the enhanced viral replication 
seen with PA-X expression is most likely due to promotion of the polymerase activity. In 
addition, the longer C-terminal domain (61aa) of PA-X has stronger effect on the polymerase 
activity. In contrast, a previous study revealed that PA-X expression had no significant effect on 
viral growth of 1918 H1N1 virus in MDCK cells and reduced viral pathogenicity in mice (Jagger 
et al., 2012). Additionally, other previous studies showed that PA-X deficient pH1N1 and H5N1 
viruses increase viral replication in A549 cells or Vero cells along with higher polymerase 
activity and enhanced viral virulence in mice compared to corresponding wild type viruses (Gao 
et al., 2015b; Hu et al., 2015). These results indicate that the effect of PA-X expression on viral 
replication and pathogenicity is virus strain-dependent. Interestingly, we showed that PA-X 
deficiency in pH1N1 virus resulted in decreased viral replication and polymerase activity in 
vitro, whereas Gao et al. showed that loss of PA-X expression in pH1N1 virus enhanced viral 
replication with a higher polymerase activity than  the  wild type virus (Gao et al., 2015b). One 
reason for the discrepant results on the PA-X deficiency in pH1N1 virus between two studies 
could be due to the different mutation approaches used in the frameshifting site to inhibit the PA-
X expression. Whether different mutation approaches such as UCCUUUCGU to UCCUUCAGA 
used in our study, and UCCUUUCGC to AGCUUCAGA in the previous study induce different 
expression levels of PA-X protein leading to this discrepancy remains unknown and will be 
investigated in future studies.  
The virus-induced host shutoff activity is expected to help the virus avoid the host 
antiviral responses by inhibiting antiviral factor expression (Narayanan et al., 2008; Vreede & 
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Fodor, 2010). Influenza virus infection can cause shutoff of host protein synthesis to inhibit host 
antiviral defense and allow viral replication (Nemeroff et al., 1998; Noah et al., 2003; Plotch et 
al., 1981). Recent studies revealed that PA-X protein in influenza virus infection has a major role 
in host shutoff which modulates host immune response by preventing antiviral related gene 
expressions (Hayashi et al., 2015; Hu et al., 2015; Jagger et al., 2012). When we confirmed 
expression of expected PA-X proteins in transfected 293T cells with different PA-X ORF 
encoding plasmids, we could barely detect PA-X proteins because of PA-X self-suppression to 
PA-X expression plasmids (Figure 3-1B). In addition, our in vitro study showed that both full-
length and truncated PA-X can shutoff co-transfected eGFP expression (Figure 3-3). 
Furthermore, we found that PA-X expressions in CA09 virus resulted in reduced levels of pro-
inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-12), type Ι IFNs (IFN-α and IFN-β) and type 
ΙΙ IFN (IFN-γ) at 3 dpi (Figure 3-7). This result may account for the reduced inflammatory 
reactions and histopathological damages in lungs of mice infected with CA09_PA-X_WT and 
CA09_PA-X_Full viruses compared to CA09_PA-X_K/O infected mice, especially at early time 
point of infection (Figure 3-5B and Figure 3-6). In addition, it is possible that inhibition of host 
antiviral response through host shutoff activity of PA-X promoted viral replication in lungs of 
infected mice, which may contribute to enhance viral virulence of both PA-X expression viruses 
in mice in contrast to the PA-X deficient virus (Figure 3-4 and Figure 3-5A). However,  previous 
studies showed that virulence of both 1918 H1N1 and H5N1 HPAIV viruses was attenuated due 
to PA-X expressions when compared to their respective PA-X deficient viruses, even though PA-
X expressions in those viruses suppressed host genes associated with immune response in vivo 
(Hu et al., 2015; Jagger et al., 2012).  One possible explanation of this discrepancy between this 
study and previous studies is that both influenza viruses, unlike 2009 pH1N1 virus, induce a 
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massive cytokine response, known as a cytokine storm which results in serious 
immunopathology and acute lung injury (Peiris et al., 2010; Perrone et al., 2008). This excessive 
immune response inhibits viral replication but causes serious pathological damage in infected 
lungs, which contribute to increased viral pathogenicity in these virulent influenza viruses. In 
contrast, absence of PA-X expression in 2009 pH1N1 virus elicits a more appropriate host 
immune response which is critical for virus clearance and reduces viral virulence. Furthermore, 
this indicates that the effects of PA-X protein on viral pathogenicity and host immune response 
are in a virus strain-dependent manner.       
Although PA-X protein is highly conserved among different influenza viruses, the length 
of its C-terminal domain varies among influenza viruses (Jagger et al., 2012; Shi et al., 2012).  
Most human and avian influenza viruses express a full-length PA-X protein with 61aa in the C-
terminal domain, while truncated PA-X protein possessing 41aa in the C-terminal region is 
common in canine, swine and 2009 pH1N1 influenza viruses (Jagger et al., 2012; Shi et al., 
2012).  We have shown that the full-length PA-X protein displays stronger host shutoff activity 
than the truncated PA-X protein in vitro and in vivo (Figure 3-3 and Figure 3-7), which is 
consistent with previous findings (Gao et al., 2015a). However, two recent studies described that 
the first 15aa in the C-terminal region of PA-X are sufficient for maximum shutoff activity, 
while the addition of 20 aa of C-terminal end is not critical to shutoff activity of PA-X (Hayashi 
et al., 2016; Oishi et al., 2015). The reason for the different observations in shutoff activities of 
truncated PA-X between these studies could be due to differences of PA-X expression systems 
used, resulting in different protein expression levels, thereby showing a difference of the host 
shutoff activity.  Because the whole PA expression plasmid was used in our study and the former 
studies,  which could generate full-length or truncated PA-X by ribosomal frameshifting (Gao et 
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al., 2015a), while PA-X expression plasmids were used in latter studies (Gao et al., 2015a; 
Hayashi et al., 2016; Oishi et al., 2015). Comprehensive phylogenetic and evolutionary analysis 
revealed that truncated PA-X appears in particular hosts such as dogs and swine which indicates 
species specificity of PA-X protein (Shi et al., 2012). Additionally, truncated PA-X protein is 
considered to be associated with the adaptation to these new hosts (Shi et al., 2012; Xu et al., 
2016). However, the role of the additional 20aa to the C-terminal end of PA-X protein remains 
unclear and further investigations are needed.  
 3.5 Conclusion 
In summary, our data indicate that expression of either full-length or truncated PA-X 
protein in 2009 pH1N1 virus helps viral replication in vitro, likely through promoting RNA 
polymerase activity, and enhances viral virulence in vivo by inhibiting host innate immune 
response through host shutoff activity. Moreover, full-length PA-X protein displays a stronger 
effect on viral replication and pathogenicity compared to truncated PA-X. Thus, our study 
provides a better understanding on the contribution of different expressions of PA-X protein to 
viral pathogenicity and the host immune response. Additional studies are needed to understand 
the role of PA-X protein in influenza virus evolution and host adaptation.      
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Figure 3-1 Generation of PA-X deficient or full-length PA-X expression recombinant CA09 
viruses 
Figure 3-1 (A) Schematic structure diagram of PA and PA-X proteins. PA-X protein contains the 
N-terminal 191aa identical to PA protein and a PA-X unique C-terminal domain (grey color box) 
of 41 or 61aa produced by +1 ribosomal frameshifting. 2009 pH1N1 virus expresses truncated PA-
X protein with 41aa in the C-terminal domain due to a stop codon (UAG) at position 42. To 
generate the CA09_PA-X_Full virus, a single amino acid substitution from UAG (stop codon) to 
UGG (W) at position 42 in the C-terminal domain of PA-X protein was introduced. Three 
nucleotide mutations in frameshifting motif were introduced from UCC UUU CGU to UCC UUC 
AGA to inhibit PA-X expression. The bold letters indicate the nucleotide substitutions. (B) The 
expression of indicated PA-X proteins was determined by western blotting analysis from 
transfected 293T cells with pCAGGS_PA-X_WT, pCAGGS_PA-X_Full or pCAGGS_PA-X_K/O 
plasmids. Mock control was transfected with the empty pCAGGS plasmid.  
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Figure 3-2 Impact of different expressions of PA-X protein on plaque morphology, growth 
kinetics and polymerase activity  
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Figure 3-2 (A) Plaque sizes formed by recombinant viruses in MDCK cells at 3 days post-
infection (dpi). (B) Growth kinetics of indicated recombinant viruses in MDCK or A549 cells 
infected at an MOI of 0.01. Each data point on the curve indicates the means of the results in 
triplicate, and the error bars indicate standard errors of the mean (SEM). The asterisks (*) indicate 
a statistically significant difference with the other groups. (C) Comparison of polymerase activities 
of vRNPs with indicated different expressions of PA-X protein in 293T cells. The grey color 
boxes indicated transfected genes. The asterisks (*) indicate a statistically significant difference 
between groups (*: p<0.05 and **: p<0.01).  
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Figure 3-3 Effects of different expressions of PA-X protein on co-transfected GFP 
expression  
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 Figure 3-3 293T cells were co-transfected for 24h with GFP expression plasmid and indicated PA 
expression plasmids encoding different PA-X forms. (A) Fluorescence images of GFP expression 
at 24h post transfection with indicated PA expression plasmids. The control was co-tranfected 
with GFP expression vectors with empty pCAGGS plasmid. (B) Relative GFP fluorescence 
intensity of each group compared to the control cells. (C) Relative expression levels of GFP 
proteins compared to the control cells using western blotting and densitometry. The GFP protein 
expressions were normalized to β-actin expression. The asterisks (*) indicate a statistically 
significant difference between groups (*: p<0.05. **: p<0.001 and ***: p<0.0001).   
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Figure 3-4 Impact of different expressions of PA-X protein on pathogenicity of CA09 virus 
in BALB/c mice  
Figure 3-4 (A) Average body weights of surviving mice in each group up to 14 dpi are represented 
as percentages of the original weight on day 0. a,b and c on the value point of each day address 
significant differences (p<0.05) between infected groups (a: CA09_WT and CA09_PA-X_K/O, b: 
CA09_PA-X_K/O and CA09_PA-X_Full, c: CA09_WT and CA09_PA-X_Full). The error bars 
indicate standard errors of the mean (SEM). (B) Survival rate of mice infected with indicated 
viruses. No significant difference was observed for mortality rate between groups. 
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Figure 3-5 Virus replication and histopathological scores in lungs of infected mice with 
either wild type CA09 or its mutated viruses  
Figure 3-5 (A) Virus titers in lungs of infected mice were determined at 3 and 7 dpi by calculating 
the 50% tissue culture infective dose (TCID50)/ml in MDCK cells. (B) Microscopic lung scores 
are presented as average scores ± SEM of three mice in each group at 3 and 7 dpi. Lungs were 
graded on the following seven criteria: Subjective percentage of lung involved in the histological 
section examined (4 point scale of 1-4); airway epithelial necrosis, neutrophilic airway 
inflammation, peribronchiolar lymphocyte cuffing, interstitial pneumonia, airway epithelial 
hyperplasia (all on a 3 point scale of 1-3); and lastly the presence and absence of hyaline 
membranes (2 point scale, 0=absent and 1=present). The asterisks (*) indicate a statistically 
significant difference between groups (*: p<0.05). The error bars represent standard errors of the 
mean (SEM). 
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Figure 3-6 H&E and IHC staining of mouse lung sections at 3 dpi  
Figure 3-6 H&E stained sections of mouse lungs infected with indicated viruses showed typical 
influenza pneumonia. Mock infected control: There are no lesions in the bronchiole. There is no 
antigen deposition in the H1N1 immunohistochemistry. CA09_WT and CA09_PA-X_Full: A 
small number of neutrophils are present in the bronchiole lumen (asterisk) and there is mild 
cuffing of the bronchiole by lymphocytes (arrow). IHC cytoplasmic staining with H1N1 antibody 
is present in the cytoplasm of bronchioles and pneumocytes (brown staining). CA09_PA-X_K/O: 
The bronchiole is filled with neutrophils (asterisk) and there is segmental loss of bronchiole 
epithelium and moderate cuffing of the bronchiole by lymphocytes (arrow).  Adjacent alveolar 
lumina are expanded by lymphocytes and histocytes. IHC cytoplasmic staining with H1N1 
antibody is present in the cytoplasm of bronchioles and pneumocytes (brown staining).  
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Figure 3-7 The mRNA expression levels of pro-inflammatory cytokines and IFNs in lungs 
of mice infected with either wild type CA09 or its mutated viruses  
 Figure 3-7 The mRNA expressions of the indicated mouse cytokines and IFNs were quantified 
from lungs of infected mice by using qRT-PCR analysis. The expression fold change of each 
group was calculated relative to the control group after normalization to 18S ribosomal RNA 
internal control using 2
-ΔΔCt
 method. Data represent the average values ± SEM of three mice in 
each group on the days indicated. The asterisks (*) indicate a statistically significant difference 
between groups (*: p<0.05. **: p<0.01 and ***: p<0.001).  
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Chapter 4 - General discussion and future prospects 
IAV is a significant human and animal pathogen that constantly circulates worldwide and 
causes considerable public health and economic problems. Despite abundant efforts to control 
IAV infection, there is no absolutely effective anti-influenza therapeutics or vaccines to date. 
One of the main reasons for this difficulty is the continued genetic mutations and evolution of 
IAVs. To overcome the limited genomic information and enhance the protein coding capacity, 
IAVs have evolved molecular strategies including ribosomal scanning, alternative spicing and 
frame-shifting (Firth & Brierley, 2012; Vasin et al., 2014; Yewdell & Ince, 2012) to translate 
multiple viral proteins from a single gene segment. This mechanism further complicates the 
pathogenesis of IAV. The eight segmented IAV genes were thought to encode 10 viral proteins, 
until a new IAV protein, PB1-F2, was identified in 2001 (Chen et al., 2001). Since 2001, seven 
additional viral proteins, PB1-N40 (Wise et al., 2009), PA-X (Jagger et al., 2012), NS3 (Selman 
et al., 2012), PA-N155, PA-N182 (Muramoto et al., 2013), M42 (Wise et al., 2012), and PB2-S1 
(Yamayoshi et al., 2016) have been discovered. However, the roles of newly discovered proteins 
and their contributions to IAV pathogenesis still remain to be elucidated. In this dissertation, we 
focused on studies to investigate the effects of two novel IAV proteins, PB1-F2 and PA-X, on 
viral pathogenicity in vitro and in vivo.     
PB1-F2 protein is a small accessory protein of IAV with various functions. Although 
PB1-F2 protein is considered an important virulence marker of IAV, its effects on viral 
pathogenicity vary depending on viral strain and host species. In the mouse model, PB1-F2 
protein enhanced the viral pathogenicity of mouse-adapted H1N1 viruses (A/Puerto 
Rico/08/1934 and A/WSN/1933) and 1918 pandemic H1N1 virus (McAuley et al., 2007; 
Zamarin et al., 2006). In the H5N1 HPAIVs, PB1-F2 protein increased viral virulence in ducks, 
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while negligible effects of PB1-F2 protein were observed on viral pathogenicity in mice and 
attenuated virulence was found in chickens with PB1-F2 protein in H5N1 HPAIVs (Leymarie et 
al., 2014; Schmolke et al., 2011). PB1-F2 protein expression in TR H3N2 SIV or 2009 pH1N1 
displayed minimal impact on viral pathogenicity in swine models (Pena et al., 2012a; Pena et al., 
2012b) while deletion of PB1-F2 in TR H3N2 SIV induced earlier clinical signs and effective 
viral transmission in turkeys (Deventhiran et al., 2015). The N66S substitution in PB1-F2 was 
previously described to contribute to increased virulence in mice (Conenello et al., 2007; 
Schmolke et al., 2011). On the other hand, this substitution in 2009 pH1N1 virus had no 
significant impact on virulence in mice and 66S in PB1-F2 protein played only a minor role in 
viral virulence in swine and ducks (Deventhiran et al., 2015; Pena et al., 2012a; Schmolke et al., 
2011). In Chapter 2, we showed that PB1-F2 protein expression in virulent H1N1 TR SIV has 
moderate effects on viral pathogenicity in swine, while PB1-F2 expression does not impact the 
viral replication and virulence in mice when compared with the PB1-F2 deficient virus. 
Consistent with findings of previous studies, the substitution N66S in PB1-F2 protein of virulent 
H1N1 TR SIV plays a critical role in high lethality in mice, while there was no effect on pigs.        
Another novel IAV accessory protein, PA-X, has shown a diverse range of functions with 
virus strain and host specificity. PA-X protein in 1918 H1N1and HPAIV H5N1 viruses reduced 
viral virulence in mice, while PA-X protein worked as a virulence factor in the H9N2 virus (Gao 
et al., 2015b; Gao et al., 2015c; Hu et al., 2015; Jagger et al., 2012). Interestingly, two previous 
studies showed opposite results of the impact of PA-X protein in 2009 pH1N1 virus in different 
mouse strains: Gao et al. found that loss of PA-X expression enhanced viral virulence in BALB/c 
mice, whereas Hayashi et al. reported that inhibition of PA-X expression attenuated viral growth 
in C57BL/6 mice in comparison with the wild type virus (Gao et al., 2015b; Hayashi et al., 
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2015). Other studies investigated the role of 20aa at the C-terminal end of PA-X protein in viral 
virulence. Gao et al. observed that full-length PA-X protein with additional 20 aa at the C-
terminal end increased viral pathogenicity of pH1N1, HPAIV H5N1 and H9N2 viruses in mice 
when compared to truncated PA-X protein (Gao et al., 2015a). On the other hand, Xu et al. 
demonstrated that truncated PA-X protein in TR H1N2 SIV improved viral replication and 
pathogenicity in swine compared to full-length PA-X protein (Xu et al., 2016). Recently, several 
studies revealed that the first 15 aa in the PA-X C-terminal domain is important for PA-X shutoff 
activity and subcellular localization; in particular six basic aa in the PA-X C-terminal region play 
a critical role in PA-X shutoff activity (Hayashi et al., 2016; Oishi et al., 2015). In Chapter 3, we 
evaluated the contribution of different expressions of PA-X protein including full-length, 
truncated and PA-X deficient forms, on viral pathogenicity of 2009 pH1N1 virus in vitro and in 
mice. Consistent with a previous report (Hayashi et al., 2015), our results indicate that either 
full-length or truncated PA-X expression increased viral replication and pathogenicity in vitro 
and in mice compared with the PA-X deficient virus. In addition, full-length PA-X with 
additional 20aa at the C-terminal end showed stronger effect on viral virulence in comparison 
with truncated PA-X form, which is consistent with the previous study (Gao et al., 2015a).  
Although most studies observed the same PA-X host shutoff activity in common with our data, 
the contribution of PA-X to viral pathogenicity appears to have a diverse range of consequences. 
 While some studies described critical roles of PB1-F2 and PA-X as virulence factors of 
IAVs (Hayashi et al., 2015; McAuley et al., 2007; Zamarin et al., 2006), others found opposite 
or no effect on viral virulence (Hu et al., 2015; Jagger et al., 2012; Pena et al., 2012b; Schmolke 
et al., 2011). Possibly, the discrepancies between these studies are attributed to the various 
factors such as virus strains used, different infection doses and genetic diversity together with 
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host factors including different host species, immune status and genetic background. 
Collectively, the outcome of IAV infections is diverse and unpredictable because the 
pathogenicity of IAV is dependent on various factors including virus and host factors. Therefore, 
a comprehensive understanding of the interactions between virus and host is required and more 
studies are needed to reveal the underlying mechanism of roles of PB1-F2 and PA-X in viral 
pathogenicity.  
Genetic analysis has shown that most avian influenza viruses express the full-length PB1-
F2 and PA-X proteins, whereas particular mammalian IAVs such as swine and human IAVs 
frequently contain the truncated forms of these proteins (Pasricha et al., 2013; Shi et al., 2012; 
Zell et al., 2007). Notably, currently circulating 2009 pH1N1 virus expresses both truncated 
PB1-F2 and PA-X proteins. This fact implies that truncation of these proteins are associated with 
evolution and adaptation of IAVs in these mammalian hosts. Thus, future studies are required to 
monitor the variations in length and substitutions of functional genetic markers in these proteins 
to predict virulence change and the pandemic potential.  
Many studies have described the multifunctional roles of PB1-F2 protein in IAV 
pathogenesis including pro-apoptotic function, cytokine modulation and inducing secondary 
bacterial infection (Chen et al., 2001; Le Goffic et al., 2010; Leymarie et al., 2014; McAuley et 
al., 2007; Zamarin et al., 2005).  PA-X protein has also been shown to have multiple functions 
such as anti- or pro-apoptotic functions, modulating inflammatory response and suppressing host 
protein synthesis (Gao et al., 2015b; Gao et al., 2015c; Hayashi et al., 2015; Hu et al., 2015; 
Jagger et al., 2012). Since these two proteins behave in a similar way or opposite way during 
virus infection, they might create a synergistic effect or a mutually antagonistic effect on IAV 
pathogenesis. Several other IAV proteins have also been shown to have comparable or dissimilar 
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functions to PB1-F2 and PA-X functions. NA, NP, M1 and NS1 proteins are known to be related 
to influenza-induced host cell death (Halder et al., 2011; Rossman & Lamb, 2009; Schultz-
Cherry et al., 2001; Tripathi et al., 2013; Zhirnov et al., 2002).  NS1 protein acts as an IFN 
antagonist and modulates host immune response with several mechanisms (Hale et al., 2008; 
Mibayashi et al., 2007; Talon et al., 2000; Wang et al., 2000). In addition, NS1 and PA proteins 
have been described that they are related to host shutoff activity by interfering with cellular 
mRNA processing or degradation of the cellular RNA polymerase II (Fortes et al., 1994; 
Nemeroff et al., 1998; Qiu & Krug, 1994; Rodriguez et al., 2007; Sanz-Ezquerro et al., 1995; 
Vreede & Fodor, 2010).  Therefore, more knowledge is required about how these proteins 
interact and work together to maintain the balance of IAV pathogenicity for the optimal viral 
replication.  
IAVs undergo continuous genomic mutations which result in complexity and diversity of 
sequences. Moreover, the protein coding capacity of IAV genomes has not been completely 
determined. Therefore, it is possible that unknown novel proteins of IAV might constantly be 
identified and evolve to interact with other IAV proteins or host factors to influence viral 
replication. More studies are needed to identify and characterize these proteins.  
Taken together, newly discovered IAV proteins, PB1-F2 in virulent TR H1N1 SIV and 
PA-X in 2009 pH1N1 virus, are involved in modulating host immune response and affecting  
viral replication and pathogenicity. It is necessary to monitor the prevalence and genetic 
alterations of these proteins in currently circulating IAVs and investigate new roles of these 
proteins as well as effects on the host for a better understanding of their contributions to 
influenza virus pathogenesis. It would be possible that uncovering the role of these newly 
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discovered IAV proteins will help to develop new strategies and potential targets for effective 
anti-influenza therapeutics.  
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